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GENETIC EVALUATION OF CYTOCHROME-P450 EXPRESSION IN VARIOUS 
REGIONS OF HUMAN UTERUS IN SMOKERS AND NONSMOKERS. 
 
Satya Vijayanand Vadlamuri 
 
 
1.Regiospecific expression of CYP1A1 and CYP1B1 in human uterus of nonsmokers: 
CYP1A1 and CYP1B1, isoforms of Cytochrome P450 enzyme, are of significant 
toxicological importance due to their role in catalytic activation of several procarcinogens.  The goal 
of this study was to investigate the expression of these isoforms in different regions of the human 
uterus.  Expression was determined in the endometrium, endocervix and squamous (exocervix) 
regions from six nonsmoking women by using RT-PCR.  The transcripts encoding for CYP1A1 
were significantly higher (p<0.05) in the squamous (exocervix) region compared to other areas.  
However the expression of CYP1B1 was significantly higher (p<0.05) in the endometrium.  
CYP1B1 expression appeared to be extremely low in a woman in the secretory stage of the 
menstural phase, relative to the endometrium of the other patients who were all in the proliferative 
stage at hysterectomy. CYP1B1 mRNA was expressed in only 2/6 patients in the squamous 
(exocervix) region and 3/5 patients in the cervix.  CYP1A1 was also uniformly expressed in the 
endometrium of all except one patient, in whom expression was minimal in the other regions.  It 
appears that variability in the expression of these isoforms may be responsible for the differential 
susceptibility to cancer in women. 
2. Influence of menstrual phase and smoking status on expression of CYP1A1 and CYP1B1 in 
different regions of the uterus: 
CYP1A1 and CYP1B1 isoforms exhibit significant role in the catalytic activation of 
procarcinogens during metabolism of PAH compounds and in estrogen metabolism.  The goal of 
this study was to investigate the expression of these isoforms in different regions of the uterus 
from smokers and nonsmokers.  Uterine tissue was obtained from women (n=22) undergoing 
hysterectomy.  Sections of endometrium (ENDO), endocervix (CERV) and squamous region 
(SR) were isolated, stored at -700C and expression was determined by RT PCR and relative 
mRNA levels were measured with respect to β-actin. A 12-fold increase in CYP1A1 expression 
was apparent in the CERV from smokers compared to nonsmokers. In the ENDO and SR a much 
smaller induction of <2-fold was observed.  No differences for CYP1A1 mRNA were explicit in 
the 3 regions when comparing the proliferative and secretory phases of the menstrual cycle.  A 
significantly higher (p<0.005) expression of CYP1B1 (~20-fold) was observed in ENDO from 
patients in the proliferative phase compared to secretory phase.  CYP1B1 expression appeared to 
be lower in smokers (by ~3-fold) in the ENDO and no measurable expression was observed in 
the SR.  These results indicate that CYP1A1 and CYP1B1 are expressed variably in different 
regions of the human uterus. The expression of CYP1B1 may be susceptible both to hormonal 
control and cigarette smoking.  The variability in the expression of these isoforms may be 
responsible for the differential susceptibility to cancer in some women. 
3. The effect of menstrual phase on CYP3A expression in human endometrium: 
The CYP3A family consists of four closely related proteins.  Of these, CYP3A3/4 is the 
most abundant P450 isoform and is responsible for metabolizing estrogen as well as a variety of 
 
therapeutic agents, whereas CYP3A7, the fetal liver form, is involved in the biosynthesis of estriol.  
The goal of this study was to evaluate the expression of these two major CYP3A isoforms in human 
uterine tissue during the proliferative (PROL) and secretory (SEC) phases of the menstrual cycle.  
Human endometrial tissue was collected from women undergoing hysterectomy (n=34), and frozen 
at -700C.  Total mRNA was extracted, quantified and RT PCR was carried out by using consensus 
primers to express CYP3A.  The PCR product of 453bp was transferred to nylon membrane and 
was hybridized with specific internal oligo probes for CYP3A/4 or CYP3A7 labeled with 32P γ-
ATP.  The relative intensity of hybridization for individual samples was determined after 
autoradiography and using image quant software.  Expression of CYP3A7 was significantly 
increased (17-fold) in the PROL compared to SEC phase, whereas no differences were observed 
(p>0.05) for CYP3A3/4.  No significant differences were observed for either of the CYP3A 
isoforms in overall comparison regardless of phase.  However, CYP3A3/4 expression was 
significantly decreased (30-fold) in smokers compared to nonsmokers (p<0.05) in SEC phase.  
Furthermore, a 40-fold and a 20-fold higher expression of CYP3A7 and CYP3A3/4, respectively 
were observed in the PROL relative to the SEC phase in smokers.  Differential expression of 
CYP3A isoforms in the menstrual phase between smokers and nonsmokers could determine the 
toxicological role of these enzymes in women.  Expression of CYP3A7 in endometrium appeared to 
be several fold higher (~10-fold) in the proliferative phase compared to the secretory phase.  
CYP3A4 expression was comparable between the two phases of the menstrual cycle.  Relatively 
minimal expression of both enzymes was observed in the cervix. The RTPCR results indicated 
differential expression of CYP3A7 in various phases of the menstrual cycle. These results indicate 
that CYP3A isoforms may be subject to hormonal regulation during the menstrual cycle in 
endometrium of premenopausal women.
 
 
Key words: CYP1A1, CYP1B1, CYP3A3/3A4, CYP3A7, Human Uterus, Endometrial cancer, 
Cervical cancer.  
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In the United States, uterine cancer is still one of the most predominant and prevalent 
cancers among women. About 50,000 cases of uterine cancer were diagnosed in 1998 of which 
36,100 were endometrial cancers and 13,700 were cervical cancers. World-wide about 400,000 
cases of cervical cancer and 500,000 cases of endometrial cancer were estimated (American 
Cancer Society, 1998).  
 
Figure: 1.  UTERUS:  Uterine organ in Panel A and Cross Section of uterus in Panel B. 
 
Figure 1 shows the structure of human uterus. Uterine cervix and endometrium are about 
10 cm apart the same organ, which show different degrees of susceptibility to cancer.  Among 
Panel A Panel B 
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smokers, the risk of cervical cancer increased by 3 -fold (p<0.05) whereas the risk of endometrial 
cancer decreased by almost 50% (relative odds ratio 0.57)(Brisson et al. 1994; Austin et al. 
1993).  Therefore, with increased cigarette consumption there is a significant increase in the risk 
of cervical cancer and statistically significant decrease in risk of endometrial cancer (Baron et al. 
1986). 
The risk factors for cervical cancer are human papilloma virus, older age, multiple sexual 
partners, etc., whereas for endometrial cancer the risk factors are obesity, estrogen use, clinical 
conditions causing hyper estrogenism, anovulation, nulliparity, etc. (Yager et al. 1996). 
Polycyclic hydrocarbons (PAHs) such as Benzo (a) Pyrene (BP) and nitrosamines are 
considered to be promutagenic.  Cigarettes contain 10-50mg of BP per cigarette, smoked foods 
have 100mg BP per kg, and environmental pollutants have PAHs as major components.  Several 
of the most common cancers occur in hormonally responsive tissues, including breast, 
endometrium and ovary in women and prostate in men (Yager et al. 1996).  The uterus, 
especially, endometrium, undergoes profound cell multiplication and cell differentiation at 
regular intervals, which are influenced by hormonal effects.  
 Cytochrome P450s (CYPs) are hemeproteins, which are induced in human tissues to 
metabolize various xenobiotics, hormones and other substrates.  CYPs oxidize the substrates 
through a process of oxidation and electron transport from NADPH. Some of these CYPs 
activate chemical carcinogens to their electrophilic forms, which can bind to DNA covalently 
and cause mutations that trigger carcinogenesis.  A principal goal of this research was to 
investigate this mechanism, which may explain these observations.  
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It is well established that cigarette smoke is one of the main causes of lung cancer. The 
convincing reason is the presence of benzo (a) pyrene like procarcinogens present in cigarette 
smoke are reactivated by phase I metabolizing enzymes of Cytochrome P450 s and usually 
detoxified by epoxide hydrolase/ glutathione - S- transferase. The BP is metabolically activated 
to BP-7, 8 diol- 9, 10-epoxide (BPDE) which is highly reactive and forms covalent adducts with 
cellular DNA which may result in mutations and/ or malignant transformation. Similar 
mechanism of bulky DNA adduct formation could be responsible in explaining possible 
endometrial and cervical cancers.  Cytochromes exhibit an active oxidizing role in estrogen 
metabolism. Smoking induces these CYPs and localized expressions of these CYPs in the uterine 
tissue could exhibit variability in inactivation, which is possible through differential degrees of 
inducement due to smoking or non-smoking. 
I. CYP1A1 AND CYP1B1 IN UTERINE TISSUE: 
 
Considering uterine sensitivity to estrogenic stimulus, it is valid to assume that any 
changes in the localized metabolism of the estrogens may significantly affect both the 
physiologic and toxicological outcome. It has been shown that enhanced metabolism of 
endogenous estrogens to catechols by Tetrachlorodibenzo-p-dioxin (TCDD) induced enzymes 
may lead to increased oxidative DNA damage and hence contribute to TCDD-mediated 
hepatocarcinogenicity in female rats (Tritscher et al. 1996). TCDD and other related carcinogens 
exert their effect by interacting with the Ah-receptors, which induce the expression of the 
cytochrome P450 family 1 genes - CYP1A1 and CYP1A2 (Walker et al.1995), as well as a 




Recent evidence suggests that CYP1B1 may be the primary E2 -4-hydroxylase (Hayes et 
al. 1996).  Although the 4-hydroxylation is a minor metabolic pathway and represents a 
relatively small fraction of the total urinary catechol-estrogen content (Fishman 1976), it has 
tissue specific importance.  For example, the 4-hydroxylation of E2 is significant in the metabolic 
control of estrogen homeostasis and in the human uterus the rate of E2 -4-hydroxylation 
approaches or exceeds that of 2-hydroxylation (Liehr et al. 1995).  Therefore, it is likely that 
localized inactivation of the estrogens in the uterus is an important determinant in the 
physiological as well as toxicological outcomes.  To date, only one report (Hakkola et al. 1997) 
exists in literature regarding the presence of these isoforms in one region within the uterus, but 
no information exists regarding the expression of both isoforms in all regions within the human 
uterus. 
II. CYP1A1 and CYP1B1 IN SMOKERS AND NONSMOKERS: 
 
CYP1A1 is the key activating enzyme, which carries out both oxidation steps required to 
form the most carcinogenic metabolite of BP, (+) benzo (a) pyrene-7, 8-diol-9, 10-epoxide 
(BPDE).  This diol-epoxide can form DNA adducts which may lead to mutations and eventually 
trigger a cascade of events leading to malignant transformations (Nesnow et al. 1995).  
Furthermore since the higher levels of CYP1A1 are induced in smokers (Conney 1982), the 
likelihood of exposure to reactive metabolites is increased even further.  Likewise, the reported 
genetic polymorphism for CYP1A1 (Rannug et al. 1995; Nebert et al. 1996) may result in 
variations in the activation of chemical carcinogens explaining differences in individual 
susceptibility (Ikawa et al. 1995; Kaderlik et al. 1995).  It is possible that the higher incidence of 
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cervical cancer in smokers and some endometrial cancer cases may be a result of exposure to BP 
or other PAHs from cigarette smoke. 
Unopposed estrogens are considered as a major risk factor in the etiology of endometrial 
cancer  (Key et al. 1988; Miller et al. 1990).  Isoforms of the CYP1 family play a major role in 
generating catechol estrogens (Dannan et al. 1986; Spink et al. 1994), e.g. human CYP1A1, 
which is involved in the activation of BP and also metabolizes estrogens (Eugster et al. 1993).  
Recently, CYP1B1 (Spink et al. 1992) has been reported to be linked to 4-hydroxylation (Hayes 
et al. 1996) of estradiol.  
III. CYP3A3/3A4 AND CYP3A7 IN UTERUS: 
 
The CYP3A subfamily of enzymes has been established as the most abundant CYP 
subfamily in humans, representing about 30% of all hepatic CYPs (Slaughter et al. 1995).  So far 
four major isoforms have been identified in humans.  They are CYP3A3, CYP3A4, CYP3A5 and 
CYP3A7, of which CYP3A4 is the predominant hepatic isoform having 98% homology with 
CYP3A3.  CYP3A7 is a human fetal liver form, first isolated as a 16-α-dehydroepiandrosterone-
sulfate hydroxylase (Kitada et al. 1987). While several CYP450 isoforms have been implicated 
in estrogen biotransformation, CYP3A4 is probably the major isoform (Aoyama et al. 1990; 
Brian et al. 1990).  CYP3A7 has been found to catalyze 16-α-hydroxylation of DHEA sulfate 
(Kitada et al. 1987).  It is believed that DHEA-s is a precursor to estrogen biosynthesis and also 
in high concentrations, DHEA-s inhibits cell proliferation (Herrington et al.1990), interferes with 
cellular respiration (Mohan et al. 1989), promotes cervical ripening (Sakyo et al. 1987) and 
inhibits placental progesterone biosynthesis (Powell et al. 1986).  Therefore CYP3A7 might be 
indirectly involved in several physiologically relevant processes in the uterus.   
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Menses is generally regarded as ischemic necrosis of a functional layer caused by 
contraction of spiral arteries dependent on sex hormone concentrations.  The endometrium 
undergoes its cycle of proliferation, differentiation and desquamation, based on levels of either 
estrogen alone or of both estrogen and progesterone.  Since the endometrium undergoes a 
constant dynamic growth phase, and cyclic variability of other enzyme expressions has been 
noted in literature (Otsuki et al. 1994), it is possible that CYP450 might also undergo similar 
cyclic variability. The goal of this research was to evaluate the expression of the glucocorticoid 
inducible (Schultz et al. 1993) CYP3A isoforms in the endometrium and cervix to investigate 
whether these isoforms undergo cyclic expression during different phases of the menstrual cycle. 
IV. CYP3A3/3A4 AND 3A7 IN NONSMOKERS AND SMOKERS: 
 
There are no references on smoking related activation of CYP3A.  Substrate specificity of 
CYP3A individual isozymes has not been fully elucidated.  CYP3A was thought to be important in 
modulating in vivo antitumor activity and levels of host toxicity.  A study in rats and hamsters has 
shown that there is no significant change in CYP3A isoforms in liver (Koide et al 1999).  However 
in another study preferential induction of CYP3A was noticed by DDT in a sex-related manner, 
which suggested that CYP regulation could play an important role in endocrine disruption (Sierra-





































BACKGROUND: In 1958 Martin Klingenberg reported the first evidence of P450 as a 
subcellular fraction of rodent liver, and thereafter during last 40 years there has been an 
explosive growth of investigations on Cytochrome P450 (CYP) (Costas 1996). Earlier studies 
with human adult and fetal liver as well as human placenta (Kapitulnik et al. 1977a; Kapitulnik 
et al. 1977b; Peldonen 1975) provided indirect evidence about the presence of multiple forms of 
CYPs.  Nebert (1987, 1989) claimed that, the P450- mediated monooxygenase system in 
mammals can be compared to the immune system, due to the fact that a seemingly endless array 
of chemical specificities for CYPs are possible. The techniques of molecular biology for cloning, 
and determining the nucleotide sequence of P450 proteins and genes (Fujii-kuriyama et al. 1982; 
Kawajiri et.al. 1984; Sogowa et al. 1985) provide the means to reveal the presence of multiple 
forms which couldn't be determined by conventional biochemical methods. 
UTERUS: As shown in Figure 1 the body of the uterus is 1cm to 1.5 cm thick which is the 
muscular portion called the myometrium. This myometrium is covered by a thin layer of mucous 
membrane called the endometrium. Endometrial tissue consists of two types of cells - glandular 
cells and stromal cells. A narrow neck is opened to the upper end of the vagina, which is called 
cervix and this is richly covered with squamous epithelium. Cervix has many cellular types. At 
the junction of cervix and endometrium is a squamous columnar junction (endocervix), which is 
typically made up of a combination or continuous transformation of columnar cells and 
squamous cells. Endometrium is always in a dynamic state of cyclic changes and is subjected to 
various levels of estrogen and progestrone influence on the development, and differentiation of 
the tissue during menstrual phase. The endometrium is a rapidly proliferating tissue, which is 
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always in an active state of mitotic changes under the influence of various hormones, cytokines, 
enzymes and various genes.  During this process, DNA adducts, if present, could be activating 
oncogenes or inactivating tumor suppressor genes that lead to neoplastic transformations.  There 
is no published evidence on this to date, although speculations are made by many. 
CARCINOGENESIS in UTERUS: Exposure to diethyl stilbestrol (DES) has resulted in 
cervico vaginal clear cell carcinoma in women and testicular cancer in men (Henderson et al. 
1988; Berne, 1992) while prolonged use of anabolic steroids and oral contraceptives is associated 
with increased risk for developing hepatocellular adenomas and carcinomas.  The most widely 
acknowledged effect of estrogens is increased cell proliferation (Nandi et al. 1995; Ethier, 1995).  
Recently, it was reported that catechol estrogens can generate metabolites that can directly or 
indirectly, through redox cycling process, generate reactive radical species causing oxidative 
DNA damage (Liehr, 1994; Liehr and Roy 1990; Li et al. 1994). Breast cancer has been linked to 
various environmental xenobiotics or their metabolites, some with estrogenic or androgenic 
agonist and antagonist activities (Falck et al. 1992; el-Bayoumy 1992; Kelce et al. 1995; 
MacMahon, 1994; Safe, 1995). 
Smoking is known to be causative for many different types of cancers- mouth, pharynx, 
larynx, oesophagus, lung, pancreas, kidney, bladder, pelvis and uterus (Schwab et al. 1997).  
Cancer of the urinary bladder is a distant cancer where smoking is also considered to be a 
causative factor (Hoffman et al. 1976; Molgavkar 1981).  The relationship between smoking 
related cancers like oral, lung, bladder, and cervical cancer has been postulated (Newell et al. 
1974; Bailar 1963).  An excess of urinary bladder tumors was seen among patients with cervical 
cancer (Bailair 1963). There is 5-to 6 -fold higher risk of developing subsequent cases of oral 
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and pharyngeal tumors among patients with cervical cancer (Newell et al. 1975). Further 
evidence from Storm and Ewertz (1985) supported that risk of cancers of the lung, oesophagus, 
bladder, and kidney occurred significantly above expectations in patients who suffered cervical 
cancer.  Among smokers, cigarette smoking appears to be a major risk factor in cervical intra 
epithelial neoplasia (CIN) and invasive cervical cancer (Hellberg 1986; Nischan et al. 1988). 
Habitual smoking and number of pregnancies increased the risk of cervical cancer (Hirose et al. 
1996).  A statistically significant dose-response relationship between cigarette smoking and 
mortality rate due to uterine cancer was established (Akiba et al. 1990). No rationale has been 
provided for explaining the relationship between smoking and cervical cancer.  There is 
overwhelming epidemiological evidence linking both of them. In spite of the reported evidence 
suggesting that the metabolic pathway involving CYP and BP inactivation are implicated in 
etiology of squamous cell carcinoma of the lung and the relationship of smoking to altered 
incidence of various malignancies in uterine tissues,  an exhaustive online and manual search of 
biomedical literature for the past 50 years has shown only eleven original research articles 
reporting CYP450 activity in human or animal uterine tissue.  The previous literature until 1985 
revolved around characterization of BP metabolism and DNA adduct formation (Dorman et al. 
1981; Mass et al. 1981).  It was reported that BP metabolites bind to DNA in endometrial tissue 
cultures (Kaufman et al. 1980; Wilbanks et al. 1980; Dorman et al. 1981; Mass et al. 1981).  
The role of BP is linked with lung cancer. The schematic representation of carcinogenic 
effect from cigarette smoke is given in following Figure 2.1, as summarized by Mohamadi A 





Figure: 2.1 Sequence of events leading to carcinogenic effects from cigarette smoke 
(MASarkar, 1992) 
 
Carcinogenesis and cellular transformation is a multistep process, starting with initial 
DNA lesions progressing through impairment and finally loss of normal cellular growth control 
and gain of invasive and metastatic properties. A number of specific p53 mutations have been 
identified in many human cancers. The molecular spectrum of p53 mutations has been 
documented well especially in hepatic cancers, skin and lung cancers.  Cigarette smoking is a 
major risk factor for the incidence of lung cancer.  Benzopyrene in cigarette smoke, causes p53 
hot spot mutations at codons 157, 248 and 273 in lung cancer. A dose responsive increase of G to 






























Cigarette smoke contains many procarcinogens like (BP), which is a widely studied compound.  
BP present in cigarette smoke is activated by CYP p450 enzymes such as CYP1A1 to form 
epoxides which are potentially toxic. These are converted to comparatively less toxic substances 
such as trans-dihydro diols by enzymes like epoxide hydrolase (EH).  Subsequent oxidation 
results in formation of diol-epoxides, which are toxic.  (+) anti  BP-7,8 diol 9,10-epoxide 
(BPDE) exhibits remarkable potency as a carcinogen on mouse skin and lungs of newborn mice.  
DNA-BPDE adducts modify normal DNA structure and function (Peldonen et al. 1980).  These 
adducts also have carcinogenic potency in many animal and in vitro systems (Brookes et al. 
1964; Goshman et.al. 1967; Shen et al. 1980; Nakayama et al.1984). BPDE- DNA adducts have 
also been found in the squamous cells of invasive cervical carcinoma patients (Shamsuddin 
et.al.1988).  Although the correlation between CYP1A1 and BP metabolism was well 
established, carcinogenicity depends on various other related mechanisms like DNA repair 
mechanisms, alternative detoxifying mechanisms and individual susceptibility, etc. Therefore, it 
is possible that individual variation in the activity of CYP enzymes could activate the 
procarcinogens in cigarette smoke and make some of the smoking patients predisposed to uterine 
cancer. 
DRUG METABOLIZING ENZYMES, SMOKING and UTERINE CANCER: 
Cigarette smoking can alter the activity of drug metabolizing enzymes like cytochromes, 
which are involved in metabolizing procarcinogens.  Lung cancer patients who were heavy 
smokers have exhibited higher activities of aryl hydrocarbon hydroxylase (AHH) and epoxide 
hydroxylase (EH) than nonsmokers.  In recent smokers, AHH in lung tissue was positively 
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correlated with level of tobacco smoke derived DNA adducts.  Epidemiological evidence 
suggests that cervix and endometrium may be differentially affected by cigarette smoking. 
Differences in enzyme activity in combination with other factors like DNA repair, genetic 
polymorphisms in p4501A1 enzymes (Nebert et al. 1989), HPV infections, and immunological 
status of the individuals will determine the individual susceptibility to uterine cancers. There is 
ample evidence suggesting that there is correlation between cervical cancer and human 
papilloma virus (HPV) (Durst et al. 1983; Shiratori et al. 1987). DNA ploidy patterns were 
reported to be correlated with cervical intraepithelial lesions (Bibbo et al.1989). It can be 
speculated that HPV infection could be an initiating factor whereas smoking related adduct 
formation could serve as promoters of the neoplastic lesions.  The reduced risk of endometrial 
cancer in smokers was linked to alterations in the levels of endogenous estrogens (MacMahon et 
al. 1982).  Therefore it was argued that reduced risk of endometrial cancer among smokers could 
be due to reduced exposure to free or total estrogenic activity (Barber et al. 1989; Khaw et al. 
1988).  Recent evidence suggests that metabolites of estrogens such as reactive quinones 
generated from catechol estrogens may act as chemical carcinogens by binding to DNA forming 
DNA adducts (Li et al. 1994; Liehr et al. 1990). Therefore, it is possible to have many 
confounding factors in the etiology of uterine cancer, and cigarette smoking could be one of 
many such factors. 
A nonspecific substrate for various CYP enzymes has been reported in uterine tissues, 
which was formed by hydroxylation of cyclohexane (Senler et al. 1985). These investigators 
studied only myometrium and leiomyoma conditions possibly due to the abundance of tissue 
availability and incidence of clinical cases. It is therefore likely that more proliferative 
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endometrial epithelium and cervical squamous and columnar cells may have measurable CYP 
activity especially after being exposed to prolonged smoking, which is likely to induce the 
enzyme. Recent studies revealed the role of CYP enzymes in uterine tissue especially CYP3A7, 
which was observed in six out of seven cases correlating to steroid metabolism (Schuetz et al. 
1993).  Tissues obtained in late proliferative or early secretory phase of menstrual cycle had the 
highest activity of BP binding to DNA whereas no significant difference on BP metabolites were 
observed on similar evaluation of endometrial tissue cultures of smokers and nonsmokers (Mass 
et al. 1981). 
One of the earlier experiments involved insertion of a bees wax thread soaked in 
3-methylcholanthrene (3-MC) into the uterus of rabbits. When inserted in a fixed position at 
various sites of uterine cavity, 3-MC has shown carcinogenic effect on endometrium and cervix 
(Merriam et al. 1960; Wentz et al. 1981). This suggested that the neoplastic transformation could 
be due to local activation of PAHs like 3-MC by CYP enzymes. 
There are other constituents in cigarette smoke like nitrosamines and other PAHs, which 
are carcinogenic. However, the focus is on BP which is a more potent carcinogen and commonly 
seen in the environment also. Its metabolism has attracted a great interest for investigations in 
animals (Gelboin et al.1980) and in humans (Shimada et al. 1989; McManus et al.1990). 
CYP1A1 and CYP1A2: BP in cigarette smoke is metabolized primarily by CYP1A1 and 
CYP1A2, which form reactive metabolites yielding covalent adducts that are likely to result in 
mutagenicity.  In heavy smokers, this possibility is aggravated by activating these CYP enzymes 
in some tissues leading to various degree of predisposition. So, cigarette smoking not only results 
in exposure to procarcinogens like BP, but also increases the levels of CYP enzymes in various 
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tissues.  CYP1A2 is also significantly induced in smokers.  This isozyme activates 2-
acetylaminofluorene (AF), 2-naphthylamine (NA), 4-aminobiphenyl (ABP) and several other 
heterocyclic amines to their proximate N-oxide metabolites (Butler et al. 1989). The arylamines, 
NA and ABP are also found in cigarette smoke along with BP which are procarcinogenic. 
CYP1A2 is less understood than CYP1A1 because of the difficulty in studying it, owing to lack 
of expression in established cell lines and rapid decrease of expression in isolated hepatocytes.  
Nuclear run on analysis has indicated that induction of CYP1A2 by aryl hydrocarbons doesnt 
occur through a transcriptional mechanism but through mRNA stabilization process (Kimura et 
al. 1986; Pasco et al.1988; Silver et al. 1988). The role of several CYP450 isoforms in catalyzing 
the hydroxylation of cortisol, testosterone, androstendione, estradiol and progesterone has been 
established (Berliner et al. 1956; Guengerich et al. 1988; Turkey et al. 1985; Lipman et al.1962).  
However, it is not clear whether these reactions in the liver have any physiological importance, if 
any, or simply serve as accessory elimination pathways.  We have shown in our lab that the 
uterus, specifically endometrium and cervix, expressed differential transcription levels of 
CYP1A1 and CYP1B1 mRNA (Vadlamuri et al. 1998) and it is likely that these extrahepatic 
CYP450 participate in tissue specific biotransformations which might be of physiologic 
relevance. 
CYP1B1:  Recently cDNA clones of mouse, rat, and human CYP1B1 have been reported 
(Savas et al. 1994; Sutter et al. 1994).  CYP1B1 enzyme is constitutively expressed in low levels 
in many tissues including heart, brain, liver, placenta, lung, kidney, skeletal muscle, spleen, 
thymus, prostate, testes, ovary, small intestines, colon, and peripheral blood leucocytes.  The 
enzyme was inducible by TCDD in a keratinocyte cell line. Its role in rat has been reported to be 
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by oxidation of 7,12 dimethylbenz[a]anthracene (Savas et al. 1994). The human CYP1B1 was 
recently characterised whose role has been suggestive in estradiol metabolism (Suter et al 1994; 
Trischer et al. 1996). Recent evidence suggests that CYP1B1 may be primarily involved as E2-4-
hydroxylase enzyme, although the 4-hydroxylation is a minor metabolic pathway and represents 
a relatively minor level of urinary catechol estrogen content (Fishman et al 1976). It has tissue 
specific importance, for example the 4-hydroxylation of E2 is significant in the metabolic control 
of estrogen homeostasis and in the human uterus the rate of E2-4-hydroxylation approaches or 
exceeds that of 2-hydroxylation (Liehr et al. 1995). Therefore, it is likely that localized 
inactivation of the estrogens in the uterus may be an important determinant in the physiological 
as well as toxicological outcome.  The existence of different isoforms of CYPs in various levels 
in different regions, impart specificity and characterstic metabolic capacity to each organ. 
Therefore, the role of these enzymes was considered important in our studies. 
CYP3A group: Existence of CYP3A enzymes in the human endometrium was reported by 
Schuetz et al. (1993) through positive reactivity on immunoblots with antibodies of CYP3A7.  
However very little CYP3A3/4 was observed in the endometrial tissues.  The catalytic specificity 
of estradiol has not yet been established, however similar to other CYP3A enzymes, CYP3A7 
mediates testosterone 6 β hydroxylation.  CYP3A7 has been found to catalyze 16 α -
hydroxylation of dihydroepiandrosterone to estrogen.  This finding adds a new dimension to 
etiology of endometrial carcinoma since high levels of CYP3A7 will result in increased 
estrogenic exposure which is likely to predispose the individual to development of endometrial 
cancer. Recently CYP3A7 and CYP3A4 were observed in endometrial tissues where they 
induced DNA adduct formation during tamoxifen therapy (Hukkanen et al. 1998). In a study 
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conducted by Environmental Epidemiology branch of National Cancer Institute, it was reported 
that the relative risk of cervical cancer in heavy smokers is about four times as great than that of 
nonsmokers (Brinton et al. 1986). The mucus obtained by cervical washing from smokers was 
tested to be mutagenic in in vitro testing (Holly et al. 1986). Further, in smokers with 
intraepithelial neoplasia, levels of nicotine and its major metabolite cotinine, both of which are 
present in cigarette smoke, were detected in cervical mucus at levels similar to those seen in 
serum (Hellberg et al. 1988). This evidence confirms that some chemicals and metabolites 
present in cigarette smoke reach distant organs in the body like the cervix. The evidence that 
BPDE-DNA adducts are seen in squamous cells of patients with invasive cervical carcinoma 
indicate that BP in cigarette smoke reaches the uterus (Shamsuddin et al. 1988). Although there 
is vast evidence correlating HPV infection with cervical cancer, the population studied didnt 
include smokers.  Recent papers suggest that HPV may be less of a risk factor than once thought 
(Reeves et al. 1989). Thirty percent of patients who were tested negative for HPV had high-grade 
cervical intraepithelial neoplasia compared to 15% who were HPV positive.  This implies that 
there is a mechanism, other than HPV, which is important in cervical cancer.  It could be 
possible that a pro carcinogenic mechanism was initiated first and then neoplastic transformation 
was done with the help of HPV.  A similarity could be drawn for this hypothesis with the 
findings of 1938 where malignancy was experimentally induced with exposure of benign lesions 
to papilloma virus. It was shown that coal tar induced benign skin lesions in rabbits which were 
rapidly converted into malignant tumors when rabbit papilloma virus was given by intravenous 
injection (Rous and Kidd 1938).  Therefore, if the cells in cervical squamosa respond to 
carcinogens like BP from cigarette smoke, as the cells in lung, a similar mechanism could exist 
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for both cervical and endometrial cancer. There is evidence that women who smoke reach 
menopause earlier than those we dont (Daniell et al. 1978). Also, decreased levels of 
endogenous estrogens in smokers imply that reduced incidence of endometrial cancer could be 
due to reduced tissue exposure to total estrogenic activity (Barber et al. 1989; Khaw et al. 1988).  
This is further supported by epidemiological data on increased risk of endometrial cancer among 
the users of conjugated estrogens (Ziel et al. 1975).  The role of estrogen receptors has yet to be 
investigated since estrogen receptor antagonists like tamoxifen used in breast cancer patients 
didnt limit the incidence of uterine cancers, particularly endometrial cancers (Fornander et al 
1989; Spinelli et al. 1991).  Therefore, it is likely that other mechanisms may contribute to 
endometrial cancers. 
CYTOCHROME P450, ESTROGEN METABOLISM and UTERINE CANCER: The metabolic 
pathways of estrogens reveal that CYP 450 enzymes are involved in various stages of menstrual 
cycle through hydroxylation reactions.  The CYP dependent hydroxylations produce inactive 
catechol estrogens such as 2-hydroxy estradiol or estrogen agonist like 16α hydroxyestradiol 
(Michnovicz et al. 1986).  In humans estradiol metabolism is primarily mediated by CYP1A2 
(Dannan et al. 1986) and to a lesser extent by CYP1A1 and CYP3A4 (Guengerich et al. 1987; 
Roy et al. 1991). There is evidence that 16 α hydroxylation has correlation with cases of 
endometrial cancer (Fishman et al. 1984).  Increased 2-hydroxylation is linked to reduced risk of 
endometrial cancer (Michnovicz et al. 1986). These findings suggest that shunting the estrogenic 
pathway in such a way that reducing 16 α hydroxylation and in turn increased 2-hydroxylation 
by CYP1A2 and CYP3A4, could possibly reduce the risk of endometrial cancer.  It was shown in 
rats that 2-hydroxy estrone gets converted to 2, 3 estradiol quinone, which binds tightly to 
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CYP1A1. This binding results in elimination of Ah hydroxylase activity in kidney as reported by 
Roy et al. in 1991.  So, if the endometrium behaves like kidney, BP activation through CYP1A1 
is likely to be bypassed because formation of BPE, a procarcinogen, is not accomplished. These 
CYP enzymes have in particular links with estrogen metabolism.  The smokers have shown a 
marked increase of 2- hydroxylation of estradiol in liver (Michnovicz et al. 1986). This 
hydroxylation was modulated by CYP1A2 (Dannan et al. 1986) and also by CYP1A1 (Roy et al. 
1991) and CYP3A4 (Guengerich et al. 1988). During a reversible metabolic pathway, estradiol 
produces 2-hydroxy estrones and 2-methoxy estrones or 16 α hydroxyestrone and estriol. These 
possess potent estrogenicity (Michnovicz et al. 1986). The 2-hydroxylation of estrogens are 
devoid of peripheral estrogenic activity and high levels of estrogens in plasma are linked to 
endometrial cancer (Fishman et al. 1984). Therefore, smokers who have excessive 2-
hydroxylation might be showing reduced incidence of endometrial cancer. Recent evidence 
suggests that 2-hydroxylated metabolites could be converted to quinones, which inactivate 
CYP1A1 at least in hamster kidney (Roy et al. 1992). The CYP3A4 which has a wide substrate 
specificity was implicated in activation of hepatocarcinogen like aflatoxin, so this isozyme may 
have an active influence along with other CYPs.  Estrogens were the main driving force for 
carcinogenesis with progestins reversing or preventing some of these changes (King 1983) as 
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Figure: 2.2 Estrogen and Progestin impact on metastasis (king et al. 1983). 
 
 Increased proliferation assists in generation of errors such that genetic changes are 
accelerated (Loeb et al. 1994; Eshleman et al.1995).  Estrogens induce apoptosis in the 
endometrium.  Any disruptive change can disturb this link.  A pivotal gene linking proliferation 
and apoptosis is p53 gene, which was inactivated in 20% of endometrial carcinomas (Homesley 
et al. 1994).  As menstruation is a consequence of progesterone production and withdrawal, 
inadequate menstrual loss could explain some more risk factors. Estrogens sensitize the cells to 
progestin action by increasing PR levels, while progestins downregulate estrogen effects by 
decreasing ER levels through increasing the catabolism of estradiol by induction of estradiol 
dehydrogenase and differentiation (King et al.1983). Both estrogens and progestins influence 
proliferation via their own receptors, which are nuclear transcription factors (King et al. 1992) 
 
 22 
Cervical carcinoma is a sporadic cancer for which no familial form has yet been 
identified, and which so far has not been associated with any inherited syndrome.  Loss of 
heterozygosity (LOH) in primary cervical carcinomas was initially reported on chromosome 3 in 
the region 3p14-21 in a small series of nine heterozygous cases (Yokota et al. 1989).  A common 
region of deletion was identified at chromosome 3p13-14.3 with 6 out of 7 cases showing loss of 
heterozygosity at this region.  Chromosome 11 holds promise of another tumor suppressor gene 
important in cervical carcinomas.  LOH has been described in 36% of cases at c-Ha-ras locus on 
chromosome 11p (Riou et al. 1988). Similarly there could be involvement of other tumor 
suppressor genes in cervical cancer which calls for further investigation. 
There are in vitro studies of DNA adduct formation in endometrial cells, which are 
influenced by hormonal status (Dorman et al. 1981). Cigarette smoke contains many pro 
carcinogens like PAHs (BP) which are strongly implicated in cancer incidence. Other substances 
like nitrosamines and 4-methyl nitrosamino-1- (3-pyridyl)-1-butanone (NNK) are also present in 
significant levels among other 50 or more carcinogens present in tobacco smoke.  BP is 200 
times more potent than the other carcinogens (Lavoie et al. 1987; Hecht et al.1988).  The 
proposal to study in controlled environment with animal models is not feasible due to the small 
size of uterus, and thereafter, small amounts of tissues in various regions of uterus render such 
studies virtually impossible. Further menstruation is unique to primates and in laboratory models 
we miss this regulatory mechanism which might elicit an important mechanism. The mechanism 
of BP causing cancer cant be established by direct studies in humans.  However indirect 
evidence suggests the BP activation can initiate carcinogenesis.  100% of animals receiving low 
intravenous doses of BPDE developed tumors in lung (Conney et al. 1982).  
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There is ample evidence that smoking is associated with lung cancer in humans. AHH 
activity as a measure of CYP1A1 was found to be high in smokers and its association with 
peripheral adenocarcinoma of lung was well established (Anttila et al. 1991). Smokers have 
shown greater BPDE-DNA adducts which are suggestive of carcinogenic precurssors (Geneste et 
al. 1991).  The smokers with homozygous rare allele of CYP1A1 locus exhibited higher risk for 
lung cancer in comparison with other genotypic combinations (Kawajiri et al. 1990). Therefore, 
based on the similar mechanism of lung cancer we would like to evaluate the genetic make up of 
uterine cancer with respect to toxicological activation by CYP enzymes especially CYP1A1, 1B1 
and 3A3/3A4 and or 3A7.  The relative abundance of these important isozymes will be studied in 



























DESCRIPTION OF PROBLEM 
 
 
It was widely reported that cervical cancer is predominantly seen among women with a 
history of prolonged smoking whereas the incidence of endometrial cancer is decreased by 
almost 50% in post-menopausal women who are smokers. These two regions - endometrium and 
cervix, are less than 10 cm apart in the same organ yet exhibit different carcinogenic property.  
This differential disposition could be explained through metabolic pathways of cytochrome P-
450 (CYP). Some of these CYP s activate chemical carcinogens to their electrophilic forms 
which can bind to DNA covalently and cause mutation that trigger carcinogenesis.  Among the 
various CYP s, CYP1A1, CYP1B1, and the CYP3A family are primarily implicated due to their 
metabolic pathways involving polycyclic aromatic hydrocarbons such as benzo (a) pyrene, 
estrogens, steroids etc. Therefore, the goal of the study was to investigate the expression of these 
CYP isoforms in different regions of the uterus among smoking and nonsmoking women. 
BP as already known, is usually metabolized by CYP enzymes - CYP450 1A1 and 1A2 
(Figure 3.1). We propose that BP, the potent procarcinogen present in cigarette smoke, gets 
transported to many tissues in the body including uterus.  It gets metabolized into BPDE through 
metabolizing enzymes such as CYP1A1 and CYP1A2 and CYP3A3/A4 in various tissues such 
as lungs, uterus, etc.  The BPDE, thus available in some parts of uterus, is likely to bind to DNA 
in the various regions of uterine tissue, which can cause mutation or activate oncogenes. 
The proposed scheme of BP metabolism relevant to our hypothesis is given in the following 














Figure: 3.1 Proposed Biotransformation scheme for Benzo(a)pyrene (BP) (Mohamadi A 
Sarkar, 1992. NCI grant # CA-62369) 
 
 CYP enzymes also are involved in estrogen metabolism.  These enzymes have an active 
role in endometrium especially where role of estrogen was predominantly seen.  We propose the 
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Figure: 3.2 Proposed metabolic scheme for estrogens modified from Yager et al (1996)  
 
The CYP enzymes like CYP1B1 and CYP3A group (especially CYP3A3/4 and 
CYP3A7) are actively involved in estrogen metabolism. These enzymes also indirectly influence 
the carcinogenicity through estrogen mediated pathway.  The metabolites of CYP enzymes are 
hydrophilic which can conveniently form covalent structures with DNA if not excreted fully. The 
DNA is in active state of multiplication in uterus due to cyclic changes. This offers an immediate 
possibility to influence tumorigenesis. 
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In heavy smokers the problem of over expression of CYP enzymes contribute to the 
formation of excessive reactive metabolites possibly due to excessive release of BP into tissues 
and accelerated CYP activity. There is ample evidence showing that free estrogens contribute to 
incidence of breast cancer. The cytochrome mediated metabolism of estrogens releases free 
catechol estrogens. Therefore sensitive tissues in uterus get exposed to these estrogens which are 




The levels of one or more of CYP enzymes were involved in the activation of benzo (a) 
pyrene which may be causing the increased risk for cervical or endometrial cancer.  Smoking 
induces the activation of CYP1A1 and /or CYP1A2, which may be a major cause of cervical 
cancer.  Induction of those isozymes might decrease the risk of endometrial cancer due to 




1. To investigate and identify the Cytochrome P- 450 expression viz.: CYP1A1, 
CYP1B1, and CYP3A group in the endometrial, endocervical and/or squamous cell 
regions (exocervix) of human uterus. 
 
2. To evaluate the intensity of expressions at mRNA level in various regions of the 
uterus. 
 
3. To analyze the expression levels of CYP1A1, CYP1B1, CYP3A3/A4 and CYP3A7 in 
women at various phases of their menstrual cycle. 
 


























MATERIALS AND METHODS 
 
Materials and Equipment used: 
 




The protocol involving collection of tissue samples from patients was approved by the 
West Virginia University Institutional Review Board.  The uterine tissue samples were collected 
from women undergoing hysterectomy for various benign clinical conditions.  Clinical history and 
other demographic details were obtained from clinical records. The format employed to collect 
data is presented in Appendix: E. 
 
1. Tissue Procurement 
Uterine tissue was obtained initially from six non-smoking pre-menopausal women 
undergoing hysterectomy for benign indications. The tissues were collected within 30 minutes of 
surgery, from three different regions of the organ, carefully sectioned to maintain sampling 
consistency.  The endometrium was obtained by scrapping the posterior surface of the inner 
lining of the fundus of the uterus.  A thin layer of tissue was excised from the cervical canal at 
6o clock position, to include the endocervix and squamocolumnar junction.  The ectocervix or 
squamous (exocervix) region was sectioned from the anterior region of the cervical.  The tissues 
were collected in separate containers and stored immediately at -700C. 




Figure: 4.1  Tissue sampling procedure 
 
Initially the samples were collected from six patients and RNA extraction was done. 
Subsequent to analyzing these samples for the expression of CYP1A1 and CYP1B1 and 
optimizing the PCR protocols, tissue procurement continued for a total of 36 patients in a similar 
fashion over a period of 2 years.  The limitation of obtaining tissue samples from clinical 
subjects was compounded due to competitive requirements of tissues for pathological studies, 
clinicians preferences and patient willingness. 
2. RNA Procedures 
RNA extraction 
 
Total RNA was extracted from the tissues by homogenizing the tissue in liquid nitrogen 
and quickly transferring to 3 ml of RNA STAT-60 (Tel-Test inc., Friendswood, TX) reagent.  A 
Size of tissue obtained after sampling from a
typical uterus
Typical section of 
myometrium Typical scrapping of endometrium




standard extraction protocol involving RNA STAT-60 kit was used, yielding 50µg - 100 µg 
RNA from 50-300 mg of tissue.   
RNA quantification 
 
RNA concentrations were measured at 260nm on a Beckman UV spectrophotometer and 
the Abs 260/280 was >1.5 for all samples.  The procedure to operate the UV spectrometer was as 
per the manual.  The RNA concentrations were calculated after adjusting to the dilutions used in 
measuring the absorbance.  The final concentrations of the samples are provided in Table in 
Appendix: F. 
RNA quality analysis 
 
The extracted RNA was run on 1.2% agarose formaldehyde denaturing gel 
electrophoresis to check the quality of RNA isolated. The quality of RNA was checked for DNA 
contamination, degradation due to RNases and also visual verification of 28S and 18S bands.  
3. Reverse - Transcription polymerase chain reaction (RT-PCR) of CYP mRNAs 
cDNA was synthesized  in a total volume of 20 µl of reaction mixture containing 2µg of 
total RNA in the reverse transcription reaction buffer (Gibco-BRL, Gaithersburg, MD), 10mM 
DTT, 25 µg/ml of oligo(dT), 0.5mM of each dNTP, 25 mM MgCl2 and 200 units of M-MLV 
reverse transcriptase (Gibco-BRL).  Samples were incubated at 420C for 50 min and the reaction 
was terminated by heating at 950C for 5 min., followed by quick chilling on ice. Target 
sequences were amplified in a 100 µl reaction mixture containing 15µM of each primer, and 5 
units of Taq polymerase (Promega Corporation). After addition of 100µl of mineral oil in PCR 
tubes (0.5ml), preincubation for 5 min at 950C was carried out followed by thirty cycles of 
amplification using a thermal cycle program consisting of 940C for 30 sec of denaturation, 620C 
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for 30 sec annealing, and 720C for 1 min of extension on Perkin Elmer - Thermal Cycler system - 
480. The PCR products (15 µl) were directly separated through 2% agarose gel electrophoresis 
and visualized by ethidium bromide staining.  Sizes of the PCR products were estimated from the 
migration of the DNA size markers (2000 kb ladder - BioRad) run concurrently.  
 
4. Semiquantitaive Analysis: 
 
Densitometric analysis was carried out on those gels where PCR products were resolved 
using an image analysis (Optimas) software.  Care was taken to follow uniform conditions 
throughout and to observe the same settings on the threshold values, microscopic lens, gel 
thickeness, quantity of PCR product loaded and other parameters. The quantitative values were 
further corrected/adjusted with the actual amount of mRNA used initially in the reaction. 
Control RNA (891-bp CAT derived) was included to verify the PCR reaction.  The 
quality of RNAs was evaluated through the expression of β−actin gene.  The primers for β−actin 
were obtained from Clonetech (Palo Alto, CA).   β−actin was positive for all tissue samples. 
Contamination with genomic DNA was ruled out from the negative results obtained when the 
RT-PCR was performed without the reverse transcriptase.  
The quantity of the PCR product was measured as a ratio of its optical density with that 
of house keeping gene  β- actin from same RNA.  β- actin was amplified with same conditions 
and same amount of mRNA.  The β- actin expression was optimized before quantifying in a 
similar way to amplified CYP1A1 and CYP1B1 genes. 
 The sequences of primers used for the PCR reaction have been identified and used by 
other researchers, therefore no further confirmation of the PCR product was considered 
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necessary initially.  However in subsequent experiments the PCR products were confirmed by 
hybridizing with internal oligos of the PCR product. 
5. Primers 
Sequences utilized for the preparation of forward (FP), and reverse (RP) PCR primers 
were as follows: 
*CYP1A1: FP: 1729-1749:  5'-TAG ACA CTG ATC TGG CTG CAG - 3' 
RP: 1856-1875:  5'- GGG AAG GCT CCA TCA GCA TC - 3' 
 
**CYP1B1: FP: +1758 - +1777 5' - AAC TGT CCA TCA GGT GAG GT - 3' 
RP: +2227 - +2248 5' - TAA GGA AGT ATA CCA GAA GGC - 3' 
 
*  Shimada, T. et al. 1989 
** Denissenko, M. F. et al. 1996. 
 
6. Endometrial dating – proliferative and secretory endometrium 
The endometrial dating was accomplished by a pathologist, using a light microscope, 
according to the technique of Hertig and classified as either proliferative or secretory.   
 
7. Patient Demographics: 
 
Patient ages ranged from 25-78 years and weight from 112-277 pounds (Tables 1 and 2).  
None of the patients were taking medications that could potentially induce CYP450 activity. 
Seven of the twenty-two patients had uterine leiomyomata (fibroid uterus) and 5 patients had 
endometriosis.  Three patients had endometrial hyperplasia, one patient had adenocarcinoma of 
the endometrium and one patient had Stage I - Squamous carcinoma of the cervix. Additionally, 
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one patient (ID # 10) had previously been treated for CIN III with a cone resection.  In the 
patient with cancer, an attempt was made to obtain tissues from non-neoplastic regions if the 
tumor area was visibly discernable. 
 
8. Titration Analysis to determine linearity for sample comparison: 
 
Serial dilution of cDNA was performed and the diluted cDNA was amplified by PCR.  
The PCR products exhibited excellent linearity (r2=0.97) over a concentration range of 0.6 - 0.75 
µg/µl.  The correlation was evaluated by comparing the optical density of the PCR product, 





The probes used to confirm the PCR products were oligos identified from internal 
sequences of the amplified fragment.  The sequences are 18 nt and 17 nt long from  antisense 
strand in the coding region of CYP1A1 and CYP1B1, respectively.  
Probe for CYP1A1: 5'- TAG GGG CAG GCA GGA TCC-3' (1780-1798) 
Probe for CYP1B1: 5'- CTC CCA GAA GCT CCT GC - 3' (2509-2526) 
10. Southern Blot analysis: 
 
PCR products were analyzed by electrophoresis with ethidium bromide staining on 2% 
agarose gel with TBE buffer. The DNA markers (Bio-rad) were loaded to assess the sizes of the 
fragments.  After electrophoresis the gels were denatured and blotted to Zeta probe Nylon 
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membrane (Bio-rad) with 10x SSC overnight.  Other sets of blots (transfer membranes) were 
also prepared where transfer was done by alkaline transfer method using 0.4N sodium hydroxide 
solution. Membranes, except those done by the alkaline transfer, were cross linked by a UV cross 
linker (Stratagene).  Membranes were prehybridized for one hour at 420C for CYP1A1 and 380C 
for CYP1B1 probes.  Hybridization was accomplished overnight at 420C and 380C for CYP1A1 
and CYP1B1, respectively, in the presence of formamide 50%, SDS 7%, 1M of Na2HPO4 25%, 
5M NaCl 5%, 0.5M EDTA 0.2% and Salmon sperm DNA (1mg/ml solution) 1% in final 
concentration.  After hybridization, the membranes of CYP1A1 were washed twice with 
solutions containing 2xSSC, 0.1%SDS at 360C for 15 minutes.  This step was followed by a low 
stringency wash with 0.1%SDS, 25mM Na2HPO4and 1mM of EDTA at 290C for 15 minutes 
twice and by high stringency wash once for 20 minutes at 420C.  Whereas for membranes of 
CYP1B1 the washes were done at 300C for 15 minutes twice with buffer containing 2xSSC, 
0.1%SDS followed by one wash at room temperature for 15 minutes with 0.1%SDS, 25mM 
Na2HPO4 and 1mM of EDTA.  The probes were found to hybridize with PCR fragments, which 
were detected by exposing the membranes in overnight Phosphor-imager screen. 
11. Expression of CYP3A group of isozymes: 
 
 CYP3A isozymes have 60  80% homology among all the members of the group.  As a 
result, for the individual CYP3A, false positives and cross reaction with primers could not be 
completely eliminated.  Further, the specificity of the primers for single isozyme can not be 
established in view of the close homology between members of CYP3A and individual variation 
among patients is also random.  To circumvent this difficulty in expressing the CYP3A isoforms 
we adopted an approach as suggested by Dr. Thomas A Kocarek, Institute of Chemical 
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Toxicology, Wayne State University, MI.  Accordingly, a set of common primers was designed 
using software and the CYP3A was amplified from the mRNA.  These primers were common to 
all CYP3A family of isozymes and as a result any one or two isozymes were amplified if present. 
The amplified PCR products were transferred to Zeta probe Nylon membranes and tested with 
individual probes of CYP3A3/4, CYP3A7 isozymes.  CYP3A3 and CYP3A4 have 90% 
homology in human sequences and exhibited similar induction pattern.  Hence we considered 
one probe for CYP3A3/4 isozyme. The sequence alignment and identification of the forward and 
reverse primers are given in the Figure 4.2. 
 
FP: Forward primer 
RP: Reverse primer 
 
Figure: 4.2 CYP  3A group sequences are aligned as obtained by using computer program. 




12. Primer Design for CYP3A group of isozymes: 
 
 As shown in Figure 4.2, sequences of all human CYP3A isozymes were aligned using a 
software and examined for common overlapping sequences. 





 Sequences utilized for the preparation of forward (FP), and reverse (RP) PCR primers 
were as follows: 
CYP3A  
FP: 619-636:  5'- GCC TAC AGC ATG GAT GT  - 3' 
RP: 1055-1072: 5'- TGG ACA TCA GGG TGA GT - 3' 




The probes utilized for hybridization were as follows: 
CYP3A4 :   
759-779 5' - CTT AAA AAA TTT GTA ACT TC - 3' 
CYP3A7 : 




13. Reverse - Transcription polymerase chain reaction (RT-PCR) of CYP3A mRNAs 
 
 The PCR reaction was carried out using the consensus primers for CYP3A  in the region 
of 619 nt to 1072 nt.  The target complimentary DNA (cDNA) was synthesized from total RNA 
by RT-PCR reaction catalyzed by superscript II RNase H - reverse transcriptase (RT) 
enzyme(Gibco-BRL) carried out in a Perkin Elmer - Thermal Cycler system - 2400.  First strand 
cDNA was synthesized in a total volume of 20µl of reaction mixture containing 2µg of total 
RNA in the reverse transcription reaction buffer (Gibco-BRL, Gaithersburg, MD), 10mM DTT, 
25 µg/ml of oligo(dT), 0.5mM of each dNTP, 25 mM MgCl2 and 200 units of M-MLV reverse 
transcriptase (Gibco-BRL).  Samples were incubated at 420C for 50 min and the reaction was 
terminated by heating at 950C for 5 min., followed by quick chilling on ice. The reaction samples 
were further incubated with 100 units/ml of RNase H for 20 minutes at 370C. Target sequences 
were amplified by hot start PCR at 940C in a 20µl reaction mixture containing 2µM of each 
primer and 1 unit of Taq polymerase (Promega). The sample tubes (0.2ml) were preincubated at 
940C for 1 min before the addition of Taq polymerase and followed by forty cycles of 
amplification using a thermal cycle program consisting of 940C for 20 sec of denaturation, 540C 
for 20 sec of annealing, and 720C for 1 min of extension. The PCR reaction products (10 µl) 
were separated through 2% agarose gel electrophoresis and visualized by ethidium bromide 
staining.  Sizes of the PCR products were estimated from the migration of the DNA size markers 
(2000 kb ladder - BioRad) run concurrently. 
 Control RNA (891-bp CAT derived) was included to verify the PCR reaction.  The 
quality of the RNA was examined by electrophoresis of 5µg RNA in 1.2% denaturing agarose 
gel (formaldehyde gel) and also evaluated through the expression of β-actin gene.  The primers 
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for β-actin were obtained from Clonetech (Palo Alto, CA).   β-actin was positive for all tissue 
samples. Contamination with genomic DNA was ruled out from the negative results obtained 
when RT-PCR was performed without the reverse transcriptase.  Direct sequencing of PCR 
products did confirm the target sequences with 99% accuracy with a 1% base pair mismatch.  
  
14. Hybridization analysis: 
 
 The method as given in current protocols (Frederick et al. 1987) was followed with 
some modifications. After electrophoresis the gels were denatured and blotted to Zeta probe 
Nylon membrane (Bio-rad), where transfer was done by alkaline transfer method using 0.4N 
sodium hydroxide solution.  Membranes were hybridized with the specific internal probes for 
CYP3A3/4 and CYP3A7.  
 The probes were obtained from Gibco-BRL and end labeled at the 5' end with γ 32-P 
dATP (Redivue - Amersham) using 5'-End labeling system (Promega). The probes were 
made with 10 pmoles of oligo incubated with γ- 32P ATP and T4 polynucleotide kinase in 1x  
forward reaction buffer at 370C for 30 minutes. The reaction containing the probes were 
purified by separating the unincorporated oligos with G-50 Sephadex columns (Boehringer 
Mannheim ). The specific activity obtained for the probes was 137000 cpm to 156000 cpm 
per 10 pmoles as measured in a scintillation counter. 
 The membranes were transferred to hybridization flasks without any air bubbles 
between the membranes and wall of the glass flasks.  These membranes having the CYP3A 
products were initially prehybridized with hybridization buffer at 650C for 2-4 hours.  Then 
the membranes were incubated overnight with probes (25µl final volume) in 8ml of 
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hybridization buffer. The hybridization and washes were undertaken in hybridization oven 
(Stovall). 
  Wash solutions included wash buffer containing 5X SSC, and 0.1% SDS which was 
used for 15 min at 340C, followed by buffer II containing NaHPO4 25mM, EDTA 1mM, SDS 
0.1% at 29.50C for 15 min. A final wash was done with buffer II above at room temp for 15 
minutes. The probes were found to hybridize with PCR fragments, which were measured 
after overnight exposure of the membranes on a Phosphor-imager screen. 
 
15. Reconfirmation of the probe specificity: 
 
The probes were stripped from the respective membranes by incubating in warm (370C) 
stripping solution containing 20% SSC until the buffer attained room temperature. The 
membranes were then hybridized by interchanging the probes and evaluated as to the relative 
intensities of expression of 3A4 and 3A7 on the membranes.  This process eliminated the 
possibility of any non-specific hybridization, and confirmed that the expression levels of 3A4 
and 3A7 remained similar after interchanging the probes on the same membranes to that of 
different membranes. 
16. ImageQuant Analysis: 
 
The relative abundance of hybridization was measured by using ImageQuant software 
under uniform parameters of equal area, pixels, color intensity values etc., after correcting for 
background intensity with relative areas at the same lane of fragment movement in respective 




17. Data Analysis: 
 
Statistical analyses were carried out using JMP Software (SAS Institute, NC).  
Comparisons were made using a multi-factor analysis of variance.  The values of density of the 
probe as measured in a phosphor imager were adjusted to that of initial mRNA concentrations 
and then as a ratio of its density with that of housekeeping gene - β - actin from the same RNA.  
β - actin was amplified with the same conditions and same amount of mRNA.  The differences in 
optical density of probes as obtained by computerized image analysis were evaluated between 




























1. Expression of CYP1A1 and CYP1B1 in nonsmokers: 
 
The patient demographics are shown in Table 1 for the first six patients used as a model 
to analyze the expression of CYP1A1 and CYP1B1 among nonsmokers. The findings have been 
published in Cancer Letters 122, (1998), pp 143 150. 
The age of the patients ranged from 37-48 years and weight ranged from 135-277 lbs.  
None of the patients were on any comedications that could potentially induce CYP450 activity.  
Four of the six patients had uterine leiomoyma and all except one patient were in the 
proliferative phase of their menstrual cycle. 
The expression of CYP1A1 and CYP1B1 in different regions of the human uterine tissue 
is shown in Figures 5.1 and 5.2 respectively.  The transcripts encoding CYP1B1 were uniform in 
the endometrial region for all the patients except one where it was significantly decreased 
(p<0.05).  The endometrium in this patient was in the secretory phase, whereas all the other 
endometrial tissues were in the proliferative phase.  The transcripts encoding for CYP1B1 were 
significant in only 2/6 patients in the squamous region (exocervix) and minimal in the 
endocervix.  The expression of CYP1A1 appeared to be increased in one patient (Pt. #3) in all 
three regions, yet the patient history did not give any indications to suggest enzyme induction.  
The same patient also had induced levels of CYP1B1 mRNA in the squamous region (exocervix) 
and endocervix.   A semi-quantitative analysis of the optical density of the RT-PCR products by 
densitometry yielded results as shown in Figure 5.3.  The endometrium appeared to have the 
highest degree of transcripts encoding for CYP1B1 whereas the endocervix had the least 




2. Expression of CYP1A1 and CYP1B1 in Nonsmokers and Smokers and with respect to 
Menstrual phase: 
 
Transcripts encoding for CYP1A1 and CYP1B1 mRNA were observed in different 
regions of the human uterus as shown in Figures 5.4 and 5.5 respectively. The demographics of 
all the 22 patients for this analysis is given in Table 2. The measured levels of CYP1A1 and 
CYP1B1 for all patients are given in Tables 3 and 4. There were no differences in β-actin mRNA 
levels for each sample (data not shown), confirming that equal quantities of mRNA were used in 
all analyses.  CYP mRNAs detected in samples stored at -70o C (stored for less than 3 months) 
were comparable to those extracted from fresh samples.  Electrophoretic mobility of the PCR 
products was at the expected molecular weights in all samples, enabling comparison of relative 
expression of mRNAs in the different regions from each individual. The transcripts of these two 
CYPs in all the three regions of uterus among nonsmokers and smokers are shown in Figures 5.6 
(endometrium), 5.7 (Cervix) and 5.8 (Squamous region).  No difference for CYP1A1 mRNA 
expression could be observed in the three regions when compared to proliferative or secretory 
phases of menstrual cycle. 
 
CYP1A1 and CYP1B1 in the Endometrium: 
CYP1A1 (Figure 5.4) and CYP1B1 (Figure 5.5) were expressed in the endometrium of 
all patients except Pt. #10 whose endometrium was hyperplastic. CYP1A1 was expressed in the 
endometrium of all except one patient but expression was minimal in other regions. 
 Expression of CYP1B1 was significantly higher in endometrium and extremely low in secretory 
stage of menstrual phase.  Densitometric analysis of the CYP1B1 PCR product relative to β-actin 
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mRNA indicated a 20-fold greater level of CYP1B1 expression (Figure 5.12) in proliferative 
endometrium compared to secretory endometrium which was statistically significant (p<0.05). 
Comparison of CYP1B1 expression in the endometrium from smokers and nonsmokers indicated 
an apparent reduction in the mRNA coding for CYP1B1 in smokers which was not statistically 
significant (Figure. 5.11).  This difference could be confounded due to a preponderance of 
secretory endometrium in the smoker group (6/11).  The apparent differences in CYP1B1 
expression for proliferative endometrium remained significant, even after separating the smokers 
from the nonsmokers. On the other hand, no significant differences in mRNA for CYP1A1 
(p>0.05) were observed in the endometrium from smokers compared to nonsmokers (Figure 5.9) 
and when comparing the proliferative to the secretory endometrium (Figure 5.10). 
 
CYP1A1 and CYP1B1 in the Cervix: 
The mRNA levels for CYP1A1 and CYP1B1 were variable in both smokers and 
nonsmokers (Figures 5.4, 5.5 and 5.7).   While 3/11 nonsmokers did not have measurable levels 
of CYP1A1 mRNA, detectable levels were observed in every smoker.   An apparent 12-fold 
induction in the CYP1A1 mRNA levels was observed in the smokers compared to nonsmokers 
(Figure 5.9), and one of the smokers had the highest level of mRNA of all the patients.  Overall 
the levels of CYP1B1 mRNA were lower in the cervix, with none being detected in 11/22 
patients, 5 of which were smokers and 6 nonsmokers  (Figure 5.11).  No differences could be 
observed in the expression of the two isoforms in the cervical tissue obtained from patients with 




CYP1A1 and CYP1B1 in the Squamous (exocervix) Region: 
CYP1B1 mRNA was not detectable in the squamous (exocervix) region of smokers 
(Figure 5.8) and only 2/11 nonsmokers had measurable levels, albeit Pt.#3 had significant 
expression (Figure 5.5).  
CYP1B1 expression appeared to be lower in smokers by 3-fold. Poor expression of 
CYP1A1 was also seen in the nonsmokers compared to smokers.   Approximately a 2-fold 
induction of the CYP1A1 mRNA was apparent in smokers compared to nonsmokers (Figure 
5.9).  Patient  #3 had significant expression of both CYP1B1 and CYP1A1 in this region, 
however her history was not suggestive of enzyme induction. 
 
3. Expression of CYP3A3/A4 and CYP3A7 in Endometrium and Cervix: 
 
The patient demographics are shown in Table 5. The measured levels of CYP3A3/A4 and 
CYP3A7 as ratios with respect to β actin levels are given in Table 6. The age of the patients 
ranged from 25-48 years and weight ranged from 112-277 pounds.  None of the patients were on 
any comedications that could potentially affect CYP450 levels, specifically the patient charts 
were evaluated for any drugs that could likely induce CYP3A isoforms e.g. rifampin or rifabutin.  
The endometrial tissue was classified as either in the secretory or luteal phase (n=15) and 
proliferative or follicular phase (n=19).  Two patients not included in the table did not have any 
measurable CYP3A consensus primer RT-PCR product and therefore could not be processed for 
hybridization. 
Initial probing evaluation with the consensus CYP3A primers illustrated measurable 
CYP3A expression in the cervix as well as the endometrium (Figure 5.13), however the intensity 
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was visibly lower in the endometrium (Figure 5.14) compared to the cervix (Figure 5.15). The 
expression of CYP3A4 and CYP3A7 in different regions of the same representative human 
uterine tissue is shown in Figures 5.14 and 5.15, respectively.  The transcripts encoding for 
CYP3A7 appear to be higher in endometrium obtained from patients in the proliferative phase 
(Figure 5.16) of the menstrual cycle compared to secretory phase (Figure 5.17). The CYP3A4 
mRNA appeared to be comparable between the two phases.  A semi-quantitative analysis of the 
autoradiography by the ImageQuant software yielded relative intensities, which were compared. 
The expression of CYP3A4 and CYP3A7, as measured by the relative abundance of 
hybridization, were much higher in the endometrium compared to the cervix (Figures 5.18 and 
5.19). No difference in expression of CYP3A3/3A4 was observed in different stages of 
endometrium.  The endometrium from the patients in proliferative phase had the maximum 
CYP3A7 expression levels (Figure 5.18), which was significantly greater than the secretory 
phase (p<0.05).  The relative intensity of hybridization for CYP3A4 in the endometrium 
appeared to be similar between the phases of the menstrual cycle (Figure 5.18). 
 
4. Expression of CYP3A3/A4 and CYP3A7 in Nonsmokers and Smokers: 
 
A 30fold decrease of CYP3A3/3A4 was observed among smokers than nonsmokers in 
secretory phase of endometrium. Expression of CYP3A7 was increased 17-fold in proliferative 
stage than in secretory phase in endometrium. A 40-fold and 20-fold higher expression of 
CYP3A7 and CYP3A3/3A4 were observed in proliferative to secretory phase endometrium in 
smokers (Figure 5.21b). No significant difference was noticed for either isoforms in different 
menstrual phases among overall comparison of smokers and nonsmokers. 
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There is no significant difference (p>0.5) among smokers and nonsmokers in the 
expression of CYP3A3/A4 in endometrium (Figure 5.20).  In endometrium the expression of 
CYP3A7 is also not significantly different (p> 0.08) in smokers and nonsmokers (Figure 5.21).  
In cervical region (Figures 5.22 and 5.23) also the expression of these isozymes is not 
significantly different between smokers and nonsmokers (p>0.4 for CYP3A3/A4 and p>0.3 for 
CYP3A7).  The expression of CYP3A3/A4 and CYP3A7 in endometrium and cervix for 
nonsmokers and smokers is given in Figures 5.24 and 5.25, respectively.  The results of 
CYP3A3/A4 and CYP3A7 were analyzed statistically with interactions and without interactions 
(Appendices D.2 to D.5). Models were analyzed between CYP3A3/A4 and CYP3A7 with the 
differences from that of relative expression between smokers and nonsmokers (Appendices D. 6 
to D.7), from same patients with different regions, endometrium and cervix (Appendices D. 8 to 
D.9).  The master data table as modified is given in Appendix: G.1. According to this two way 
analysis, there is no significant difference between endometrium and cervix in smokers in either 
for CYP3A3/A4 or CYP3A7 enzymes, whereas, there is a significant difference between 
endometrium and cervix in both isozymes among nonsmokers.  Between the two regions, 
endometrium and cervix among smokers, there is significant difference in expression of 
CYP3A7 over CYP3A3/A4 and similar significance was observed in nonsmokers in cervix 







































































Figure: 5.6 Expression of CYP1A1 and CYP1B1 in Endometrium – 








Figure: 5.7 Expression of CYP 1A1 and CYP 1B1 in CERVIX –





Fig: 5.8 Expression of CYP 1A1 and CYP 1B1 in SQUAMOUS







































Figure: 5.14  








































  Figure: 5.19 CYP3A levels in CERVIX 
 































































Figure: 5.21b Levels of CYP3A7 levels in PROL and SECR 



































































Note: E17, E18, E19, E20, E21 are smokers  
E22, E23, E24, E25, E26 are nonsmokers 
 
 
Figure: 5.24 Expression of CYP3A3/4 AND CYP3A7 in ENDOMETRIUM in 




Note: C33, C34, C35, C36, C37 are smokers 
 C38, C39, C40, C41, C42 are nonsmokers. 
 
 
Figure: 5.25 Expression of CYP3A3/4 AND CYP3A7 in CERVIX 



























Table:1  Demographics of Patients
Pt ID
#
WT AGE SM/NS COMEDICATION DIAGNOSIS








































TABLE: 2 Demographics of all Patients analyzed for CYP1A1 and CYP1B1 
during various stages of menstrual cycle and smoking status 
 
PT 
# STAGE WT AGE SM/NS COMEDICATION DIAGNOSIS 
1 prol 154 48 ns 
sineguam, 
diazide 
Fibroid uterus focal 
mild chronic cervicitis 
and squamous 
metaplasia 

















5 prol 142 48 ns 
drixoral, ativan, 
bc pills 
Fibroid uterus, Chronic 





2 37 ns 
imitrex, 
anaprox, lodine 
Chronic pelvic pain, 
leiomyomas, multiple 
follicle cysts 
















10 prol 112 25 sm augmentin 
Pelvic pain with 
endometriosis 










12 secr 195 35 ns progestrone. 
Vaginal bleeding, 
Endometrial atrophy on 
progestrone use, Endo 
hyperplasia, Chronic 
cervicitis, Nabothian cysts 
of cervix, Focal 
parakeratosis of exocervical 
epithelium 
13 secr 266 56 ns no 
Endometrial cancer, 
rectocele, genuine stress, 
urinary incontinence, post 
menopausal bleeding 




hyperplasia, with atypia, 
cervix showing nabothian 
cysts and focal chronic 
inflammaton. 
15 secr 120 78 ns morphine 
Uterine diseensus, 
cystocele, rectocele, fibroid 
uterus 




17 secr 181 48 sm 
sudafed, 
ibuprofen 
Heavy pain ful periods, 
pelvic relaxation, urinary 
incontinence 
18 prol 148 38 sm no Pelvic pain, endometriosis 
19 atrophic 200 62 sm ultram Severe Cervical dysplasia 






persistent pelvic pain, and 
tenderness, possible 
adenomyosis, menorrhagia. 
21 hyperplasia 213 41 sm 
depo-provra, 
tolazamide Intractable uterine bleeding 
22 prol 112 37 sm no 
Stage I and A-2 squamous 







Table: 3  CYP1A1 expression levels in various regions as ratio with
β − actin
PT id # Squamous Endometr Cervix SM/NS STAGE
1 0.12595 0.40555 0 NS PROL
2 3.96598 0.74032 0 NS SECR
3 3.35676 2.12341 1.13086 NS SECR
4 4.46956 0.54298 0.19036 NS PROL
5 3.0548 3.02123 0 NS PROL
6 1.75032 2.17854 0.96513 NS PROL
7 9.23558 2.96866 0 SM SECR
8 1.8216 6.8105 1.84731 SM PROL
9 15.7428 8.73288 16.561 SM ATROPHIC
10 1.10473 0 0 SM HYPERPLASIA
11 13.5322 2.25665 0.74667 SM PROL
12 0 12.3142 13.6697 SM PROL
13 1.13222 1.16218 0.86855 SM PROL
14 0.68485 0.05979 1.18839 SM PROL
15 1.64991 0.79901 1.47769 SM SECR
16 2.22665 1.49169 0.27886 SM PROL
17 0.7496 0.63925 0.02866 SM SECR
18 0.17768 0 0.10993 NS SECR
19 0.90688 0.18558 0.33963 NS SECR
20 0.1738 0.87274 0.19131 NS SECR
21 0.48839 1.2258 0.09724 NS SECR








Table: 4 CYP1B1 expression levels in various regions as ratio with
β−actin
PT id # Squamous Endometrium Cervix SM/NS STAGE
1 0 2.48632 0.26048 NS PROL
2 0 0.07734 NS SECR
3 2.08222 2.15973 1.72426 NS SECR
4 0 2.84938 0 NS PROL
5 0 7.03089 0 NS PROL
6 3.19936 3.07206 0.27266 NS PROL
7 0 1.55331 0 SM SECR
8 0 1.51628 0 SM PROL
9 0 0.91298 1.86394 SM ATROPHIC
10 0 0 0.365 SM HYPERPLASIA
11 0 4.53018 0 SM PROL
12 0 0.32087 SM PROL
13 0 0 0.07821 SM PROL
14 0 0.03325 0 SM PROL
15 0 0 0 SM SECR
16 0 0.05333 0 SM PROL
17 0.06335 0.03706 0 SM SECR
18 0 0.02099 0.27864 NS SECR
19 0.08079 0 0.12023 NS SECR
20 0 0.04947 0 NS SECR
21 0 0 0 NS SECR














Stage wt Age SM/NS Comedication diagnosis 
E31 C51 inactive 217 49 NS Prednisone Pelvic 
pain, 
Prolapse 
E32 C52  secr 148 36 SM* Naproxin Chronic 
pelvic 
pain 



































E39 C60 inactive 140 74 NS Synthroid, 
Cipro, Asprin, 







E40 C61 prol 270 47 SM** Cipro Hernia, 
menomet
rorrhagea 























*only one patient is black. 




Table: 6  Levels of CYP3A3/A4 and CYP3A7 as ratios with 
respective β actin levels 
 
 
ID# STAGE SM / NS 3A3 /A4 3A7 
E1 PROL SM 0 0 
E4 PROL NS 0 0 
E5 PROL SM 950517 14223601 
E7 PROL NS 2152962 91058 
E8 PROL NS 0 0 
E9 PROL NS 3128568 10664064 
E10 PROL SM 4619279 9430575 
E13 PROL NS 8971099 2659004 
E16 PROL NS 0 127022 
E17 PROL SM 6976845 19244217 
E18 PROL SM 0 0 
E20 PROL SM 7769961 5457450 
E11 SECR NS 4243992 95210 
E14 SECR NS 2403039 10567 
E15 SECR SM 26821 390583 
E19 SECR SM 432695 154682 
E21 SECR SM 42844 34066 
E23 SECR NS 6938609 81577 
E24 SECR NS 8473469 114550 
E25 SECR NS 4252467 1146260 
E26 SECR NS 5853757 1053534 
E22 SECR NS 0 904271 
E31 INACTIVE NS 16144.86 593082 
E32 SECR SM* 5188.64 59660.02 
E33 PROL NS 56258.25 1014889 
E34 PROL/CA NS 22997.22 1032549 
E35 SECR NS 5060.3 61469.89 
E36 SECR SM 109528.2 899699.7 
E37 SECR NS 374089.3 295883.6 
E38 PROL NS 33689.78 256547.4 
E39 INACTIVE NS 53867.4 1521953 
E40 PROL SM** 96553.12 428051.7 
E41 SECR NS 274711.9 574076.6 
E42 PROL NS 68775.67 29237.53 
E43 SECR SM 279421.2 101713.1 
 






     
 
 
    
3A3/3A4 and 3A7  DATA ON CERVIX  
   3A3/3A4 3A7 
C33 PROL SM 0 0 
C34 PROL SM 18427 533427 
C35 SECR SM 0 0 
C36 PROL SM 12748 59205 
C37 SECR SM 30978 615701 
C38 SECR NS 15755 1522111 
C39 SECR NS 0 922991 
C40 SECR NS 0 0 
C41 SECR NS 0 1111309 
C42 SECR NS 0 0 
C51 INACTIVE NS 8260.72 619157.8 
C52 SECR SM* 0 35017.32 
C53 PROL NS 1754.84 18999.14 
C54 PROL/CA NS 0 9095.2 
C56 SECR NS 1411.7 10089.04 
C57 SECR SM 3002.82 19757.01 
C58 SECR NS 0 -205.07 
C59 PROL NS 0 536.31 
C60 INACTIVE NS 2636.4 14631.52 
C61 PROL SM** 1422.36 8284.52 
C62 SECR NS 29144.06 9226.17 
C63 PROL NS 2312.09 14586.55 
C64 SECR SM 1941.52 7218.67 
 
 
* This is the only case who is black. 


































The CYP1A1 and CYP1B1 isoforms are key enzymes in the formation of reactive 
metabolites from procarcinogens (Juchau et al.1982; Kawajiri et al. 1991; Kociba et al. 1978) 
and therefore play an important role in determining the carcinogenic outcome.  Variability in the 
expression of these enzymes in barrier extrahepatic tissues e.g. lung (Liehr et al. 1986) may 
provide an explanation for differential susceptibility to neoplasia in some individuals.  To date, 
no reports exist regarding evaluation of the constituent expression of CYP1A1 and CYP1B1 in 
human uterine tissue.  While CYP1A1 is generally believed to be predominantly an extrahepatic 
enzyme (Liehr et al. 1996), CYP1B1 is also expressed constitutively in extrahepatic organs such 
as breast, prostate and lung (Liehr et al. 1995).  Moreover, recent findings suggest that CYP1B1 
is a key enzyme in estradiol hydroxylation (Hayes et al. 1996).  The catechol estrogens lead to 
inactivation of estrogenic activity, however, they are toxicologically active and appear to play a 
role in toxicity and tumorigenesis (Liehr et al. 1990; Lucier et al. 1991).  The mechanism for 
these toxic effects appears to involve free radicals, generated from the reductive-oxidative 
cycling of the catechol estrogens with their corresponding semiquinone and quinone forms, 
which cause cellular damage (McManus et al. 1990; Nutter et al. 1994; Shimada, et al. 1989).  
Therefore, alterations in the expression of these two isoforms may help us better understand the 
role of procarcinogen activation in human tumors of extrahepatic origin.   
In our study we have shown that CYP1A1 and CYP1B1 are constitutively expressed in 
the endometrial tissue of the human uterus which does not seem to vary significantly in 
nonsmoking women without malignant indications.  Although we observed a significantly lower 
 
 89 
expression of CYP1B1 in a patient with secretory endometrium, further investigation is indicated 
to determine if the menstrual phase could account for this observation.   It can be speculated that 
the variations in hormonal levels during the menstrual cycle may impact the expression of 
CYP1B1, particularly in regard to the endocrine regulatory role of this enzyme.  Interestingly, 
even though CYP1A1 is predominantly an extrahepatic enzyme, expression of this isoform was 
minimal in the cervix and squamous region (except for patient #3).  Probably due to proliferative 
nature of the endometrial glands and the sensitive responsiveness of this tissue to hormonal 
influences, the CYP1 family isoforms are constitutively expressed in the endometrium. 
Metabolism of estrogens is primarily hepatic, nevertheless some metabolism has been observed 
in physiologically relevant extrahepatic tissues e.g. breast (Shimada et al. 1992), uterus (Hakkola 
et al. 1996) and placenta (Sutter et al. 1994).  It is likely that the constitutive expression of 
CYP1A1 and CYP1B1 in human endometrium plays a critical role in the localized metabolism 
of estrogens.  Differential expression of these isoforms may have an impact on the extent of 
localized inactivation of the estrogens and hence may determine the physiologic and toxicologic 
outcome. 
 The study included 22 patients in whom expression of CYP1A1 and CYP1B1 in three 
different regions with respect to smoking and nonsmoking status and also different stages of 
menstrual cycle have been considered.  In particular, mRNA encoding for CYP1B1 was 
completely absent from the squamous (exocervix) region and was not expressed in cervix of 
more than half of the patients.  Moreover, significant expression of CYP1B1 was observed in the 
endometrium, which appeared to vary with the menstrual phase.  Transcripts coding for CYP1A1 
appeared to be significantly induced in the cervix of smokers compared to nonsmokers, but 
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differences in phases of menstrual cycle had no apparent effect on the expression of that 
isozyme. Such variable expression of CYP1A1 and CYP1B1, in different regions of the uterus of 
smokers and nonsmokers, could explain the differential susceptibility of smokers and 
nonsmokers to cervical and endometrial cancer. 
Variability in the expression of these enzymes in barrier and extrahepatic tissues such as 
lung (Shimada et al. 1992) and uterus may provide an explanation for differential susceptibility 
to neoplasia in some individuals.  Similar to CYP1A1, which is generally believed to be 
predominantly an extrahepatic enzyme (Masters et al. 1987), CYP1B1 is also expressed 
constitutively in extrahepatic tissues such as breast, prostate and lung (Brake et al. 1995).  These 
data confirm a recent report of CYP1B1 expression in endometrium (Murray et al. 1997).  
Moreover, recent findings suggest that CYP1B1 is a key enzyme in estradiol hydroxylation 
(Hayes et al. 1996).  Catechol estrogens lead to inactivation of estrogenic activity, however, they 
are toxicologically active and appear to play a role in tumorigenesis (Ikawa et al. 1995; Murray 
et.al.1997).  The mechanism by which these toxic effects occur involves formation of free 
radicals, generated by the reductive-oxidative cycling of the catechol estrogens with their 
corresponding semiquinone and quinone forms, causing cellular damage (Liehr et al. 1990, 
Dwivedy et al. 1992; Nutter et. al 1994).  Therefore, while CYP1A1 is a key enzyme involved in 
activation of procarcinogens from cigarette smoke and other environmental pollutants, CYP1B1 
plays an equally important role in promoting estrogen induced cancers.  
The patient demographic data (Tables 1, 2 and 3) do not indicate prolonged enzyme 
releasing therapy. However, some individual response for specific CYP enzymes can not be 
ruled out. That kind of analysis is outside the purview of this study.  So, based on the overview 
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of medication, length of use of drugs and disease conditions, it is reasonable to assume that 
expression of CYPs is modulated by factors other than drugs and disease of the patients. 
The CYP1A1 mRNA is significantly induced in smokers whereas the CYP1B1 mRNA 
appears to be down regulated.  Although, each isoform is thought to be induced via the nuclear 
ligand/Ah receptor complexes, mediated atypical induction (Eugster et al. 1993; Nebert et al. 
1994), profiles for these isoforms have been observed in other extrahepatic tissues.  For example, 
in the glomerular mesangial cell (Bowes et al.1996) as well as the liver, lung and thymus (Vogel 
et al. 1997), TCDD induces CYP1B1 more effectively than CYP1A1.  Whereas the pattern of 
induction is reversed with benzo(a)pyrene (Bowes et al. 1996), CYP1A1 is induced 
predominantly, without much effect on CYP1B1.  It seems likely that such a differential 
induction of CYP1A1 and CYP1B1 mRNA is occurring in the uterine tissue of smokers.  Not 
only are there differences between the two isoforms, but regiospecific induction of CYP1A1 
occurs in the uterus.  A 12-fold increase in CYP1A1 mRNA was seen in the cervix, whereas only 
a 2-fold induction of CYP1A1 mRNA was observed in the endometrium and squamous 
(exocervix) region.  It is well established that PAHs influence the accumulation of the CYP1A 
mRNAs by both transcriptional and post-transcriptional mechanisms (Pasco et al. 1988).  It has 
also been shown that induction of CYP1A mRNA is followed by a proportional increase in 
catalytic activity (Pasanen et al. 1988).  Since CYP1A1 is the key enzyme involved in the 
conversion of benzo(a)pyrene to highly reactive epoxides (Miller et.al. 1990), increased enzyme 
levels would generate greater amounts of  reactive metabolites. This increased CYP1A1 activity 
and expression might explain the increased risk of cervical cancer in some smokers.  Further 
evidence of carcinogenicity of PAHs from cigarette smoke in the cervix is provided by the 
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appearance of elevated levels of DNA adducts in cervical epithelium (Otsuki et al.1994).  
Interestingly, the patient previously treated for CIN III had no detectable CYP1A1 mRNA, 
probably because the atypical tissue at the squamous-columnar epithelial junction had been 
completely removed during the previous surgical procedure. 
A significantly lower expression of CYP1B1 (p<0.05) in patients with secretory 
endometrium and absence of detectable mRNA in the postmenopausal women (patients # 15 and 
#19) suggest that CYP1B1 regulation is altered during the menstrual cycle.  The endometrium 
responds to ovarian steroid hormones in a series of clearly distinct phases which characterize the 
menstrual cycle.  Estrogen dependent proliferation and progesterone dependent differentiation of 
the endometrium are well documented.  Cyclic expression of other genes during the menstrual 
cycle has been previously reported (Loza et al. 1991).   It can be speculated that hormonal 
variation during the menstrual cycle may have some impact on the expression of CYP1B1, 
particularly due to the endocrine regulatory role of this enzyme.   It is possible that the 
constitutive expression of CYP1A1 and CYP1B1 in the human endometrium plays a critical role 
in the localized metabolism of estrogens.  This is particularly relevant since some estrogen 
metabolism has been observed in the uterus (Sholl et. al 1983; Rock et al. 1994).  The 
significance of variation in expression of CYP1B1 in the menstrual cycle is borne out by the 
observation that endometrial cancer most commonly occurs in women who do not ovulate 
regularly.  Such cases commonly show a persistence of proliferative endometrium along with 
absence of secretory endometrium.  Based on our results, it can be speculated that in some 
women a differential expression of the CYP1B1 isoforms may exist, thereby increasing 
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susceptibility to exposure from catechol estrogens resulting from localized estrogen metabolism 
in the endometrium.  
It has been demonstrated that human endometrium, as well as cervix from women 
undergoing hysterectomy for benign conditions, express CYP3A4 and CYP3A7.  This 
observation supports the previous finding of CYP3A7 mRNA in endometrium from 5 pregnant 
women (Schuetz et al. 1993).  The appearance of the CYP3A isoform was documented by      
RT-PCR, and southern blot hybridization techniques.  Based on the results, it appears that human 
cervix minimally expresses CYP3A isoforms, however significant expression is seen in the 
endometrium that is highly variable, possibly due to cyclic expression.  Particularly, the 
CYP3A7 mRNA appeared to be much higher in the proliferative phase compared to the secretory 
phase.   The expression of CYP3A4 and CYP3A7 mRNA in human endometrium suggests that it 
might be an important site for intermediary steroid metabolism.  The CYP3A family is known to 
be inducible, for example the CYP3A mRNA increases in response to the administration of 
synthetic and natural glucocorticoids (Molowa et al. 1986; Scheutz et al. 1984), macrolide 
antiobiotics  (Watkins et al. 1986), rifampin and rifabutin (Oesch et al. 1996), environmental 
agents such as polychlorinated biphenyls (PCBs) and organochlorine pesticides (Scheutz et al. 
1986).  We observed an increase in the CYP3A7 mRNA in endometrium associated with the 
menstrual phase.  The possibility of enzyme induction cannot be ruled out, particularly by 
exposure to PCBs, dichlorodiphenyltrichlorethane and other persistent lipophilic environmental 
agents that are virtually ubiquitous in the general US population (Stehr-Green et al. 1986).  
However, the increase in CYP3A7 mRNA occurred consistently in the proliferative phase in 
most patients, suggesting that the changes in the amounts of endogenous substrates and 
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hormones can affect CYP3A expression in the endometrium. The reported 3 to 4-fold increase in 
endometrial tissue concentrations of DHEA-s, a known substrate for CYP3A7 (Kitada et.al. 
1987), during the secretory phase in premenopausal women (Bonney et al. 1984) coincides with 
the decreased levels of CYP3A7 seen in our study. Transcription for the rat liver CYP3A 
isoform, CYP3A1, is controlled by a nonclassical glucocorticoid receptor mediated process 
(Burger et al. 1992.).  Moreover, the synthetic glucocorticoid agonist, dexamethasone, induces 
CYP3A7 mRNA in the human hepatoblastoma HEPG2 (Beach et al. 1992) through 
transcriptional activation of CYP3A7.  These observations suggest that steroid hormones and 
their receptors play a role in the regulation of CYP3A7.  The 11 beta-hydroxysteroid 
dehyrogenase type II enzyme, a potent inactivator of glucocorticoids, is significantly lower 
during the proliferative phase compared to the secretory phase of the menstrual cycle (Smith 
et.al.1997), probably resulting in higher tissue levels of glucocorticoids.  Moreover, the 
endometrial mRNA levels of coritocosteroid binding globulin (CBG) which binds steroid 
hormones and plays a role in their transportation, were significantly higher in the secretory phase 
compared to the proliferative phase (Misao et.al. 1994).  These findings suggest that high tissue 
specific levels of CBG, in the endometrium would result in increased binding of glucocorticoids 
thereby reducing the exposure of endometrium to free glucocorticoids.  This decreased tissue 
specific exposure to glucocorticoids might account for the relative downregulation of CYP3A7 
in secretory phase, since this isoform is susceptible to glucocorticoid induction. Further 
investigations are necessary to clearly elucidate whether the increased mRNA levels of CYP3A7 
in the proliferative phase are due to upregulation, or lower mRNA levels in the secretory phase 















Both enzymes CYP3A3/A4 and CYP3A7 have exhibited a possible interdependent 
relationship in their induction in uterine tissue in smokers and nonsmokers. Only nonsmokers 
exhibited significant expression of these enzymes in endometrium, which is due to higher 
estrogen stimulus present in this tissue. Further, the endometrial tissue is in a state of continuous 
growth and DNA also is in continuous and regular replication, which explains the enhanced 
induction and expression of their mRNA.  Whereas in smokers, absence of this phenomenon 
explains that constitutive presence of smoking related procarcinogens alter the induction levels 
of these CYPs in the both regions of cervix and endometrium.  Inactivation of procarcinogens 
like BP is catalyzed by these CYPs, which are also involved in estrogen metabolism.  Therefore 
levels of CYP3A7 and CYP3A3/A4 enzymes were elevated among smokers (Figure 6.1-A).  The 
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Figure: 6.1.  The comparative analysis of CYP3A expressions in endometrium and cervix 
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differential expression of these two isozymes in the same tissue within the group of smokers and 
nonsmokers reveals similar findings and agrees with the hypothesis of CYP mediated BP 
catalysis in uterine tissue.  The smokers exhibited elevated levels of CYP3A3/A4 more than 
CYP3A7 in endometrium. Similar significance was evident in nonsmokers in cervix region.  
This explains the relative importance of CYP3A3/A4.  BP induces CYP3A3/A4, which 
participates in estrogen metabolism.  Thus, there is the least chance of overexposure of estrogen 
in endometrial tissues among smokers.  This explains the phenomenon of smokers exhibiting 
reduced incidence of endometrial cancer.  In nonsmokers CYP3A7 is significantly higher in 
cervix which possibly offers protective mechanism against estrogen exposure (Figure 6.1-B).  
Both of these enzymes have shown a balanced expression in nonsmokers endometrium and 
smokers cervix.  The absence of statistical significance may not disprove the relative roles of 
these enzymes, however the differences in the expression of both isoforms could be clinically 
significant.  The location of enhanced activity for CYP3A7 in cervix seemed to translocate to 
endometrium region among smokers possibly due to some intracellular mechanism or through 







































1.  Evaluation of cytochrome P450 expression in uterine tissue revealed that CYP1A1 CYP1B1 
and CYP3A3/A4 and CYP3A7 isoforms are constitutively expressed in endometrium, 
endocervix and squamous (exocervix) regions. The expression levels are variable in the tissues 
depending on the cyclic changes and nature of the tissue, which are also dependent on other 
metabolic stimulii. 
2.  Smoking induced the expression of CYP1A1, CYP3A3/A4 and CYP3A7 in differential 
manner depending on the stages of endometrium.  
3.  Differential expression of these isoforms was indicative of CYP involvement in smoking 
related carcinogenesis. 
4.  Expression of CYP1B1 was significantly higher in endometrium and extremely low in 
secretory stage of menstrual phase whereas expression of CYP1A1 was significantly higher in 
squamous region. A 20-fold increase in CYP1B1 was observed in endometrium of proliferative 
phase.  CYP1B1 was expressed in only 2 out of 6 patients in squamous (exocervix) region, and 3 
out of 5 patients in cervix.  CYP1A1 was expressed in the endometrium of all except one patient.  
No difference for CYP1A1 mRNA expression could be observed in the three regions when 
compared to proliferative or secretory phases of menstrual cycle 
5.  CYP1B1 expression appeared to be lower in smokers by 3-fold and no measurable expression 
was seen in squamous (exocervix) region.  A 12-fold increase in expression of CYP1A1 was 
evident in cervix of smokers compared to nonsmokers. 
6.  CYP3A isoforms are expressed in human endometrium.  Cyclic variability of CYP3A3/4 and 
CYP3A7 during the proliferative and secretory phase might be due to the variations in hormonal 
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levels in the uterus. Differential expression of the CYP3A isoforms suggests possible 
physiological function of these enzymes in the uterus. 
7.  Differential expression of CYP3A isoforms in the menstrual phase between smokers and 
nonsmokers suggests that these enzymes might play a role in the toxicological outcome in the 
uterus.  No difference in expression of CYP3A3/3A4 was observed in different stages of 
endometrium. 
8.  Significant decrease of CYP3A3/3A4 was observed among smokers by 30-fold than 
nonsmokers in secretory phase.  Expression of CYP3A7 increased 17-fold in proliferative stage 
than in secretory phase in endometrium. 
9.  A 40-fold and 20-fold higher expression, respectively of CYP3A7 and CYP3A3/3A4 were 
observed in proliferative and secretory phases in smokers.
10.  No significant difference was noticed for either of isoforms in different menstrual phases 


























FUTURE RESEARCH DIRECTIONS 
 
The identifiction of cytochromes and their characterization significantly improves our 
understanding of drug metabolism. The related genotoxic studies help to identify the 
susceptability to various xenobiotics in different individuals. However, investigations should be 
aimed at the identification of cytochrome P450s in a non-invasive, rapid and accurate manner 
sothat, bench mark susceptibility levels could be determined.  Genetic predisposition studies 
could be directed to the detection of active cytochrome gene expression and to use them as 
biomarkers. 
CYP genes appear to be primarily regulated at the transcriptional level.  Some reports 
implicate post transcriptional and post translational regulation in rabbits (Costas 1996).  It would 
seem therefore, the post translational investigation of CYP3A will give more information on how 
CYP3A is able to contribute to carcinogenesis.  
Possible small nuclear proteins associated with cytochromes may be implicated in 
activating the CYP enzymes which could be investigated or identified to substantiate the signal 
transduction process of bulky DNA adduct formation. The targetting of drugs could be 
investigated with respect to their ability to induce various CYPs. 
Following populations could be studied to gain additional insight on cancer. 
a) Populations suffering with cancer due to environmental estrogens or potentially 
exposed to PAH in smoke or cigarette smoking. 
b) Populations, those are demographically matched with smoking and nonsmoking status 
but are not suffering from cancer. 
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The expression levels of cytochrome P450s relating to various races or geographic 
localization would throw light on susceptibility to carcinogenicity due to CYP inductions in 
those populations. Further studies to assess the high risk populations of uterine cancer by 
measuring genetic expressions of CYP enzymes and the associated polymorphisms will help in 
addressing the preventive and environmental scanning measures. 
Mutation in DNA repair proteins, which are likely to contribute to excessive proliferation 
of endometrial tissue can be investigated.  This would validate that proliferation alone is the 
contributory engine for carcinogenesis. Some of the oncogene activation and disturbance in 
apoptotic response due to CYP activation could be studied in uterine cancer where investigations 
on tumor suppressor genes and oncogenes in uterine cancer are likely to be the future areas of 
interest. It is also possible that other CYP families may be involved in endometrial and cervical 
cancer development, which can be investigated further.  CYP activation is of major interest to 
drug industry for its role in predicting cytotoxicity.  It still needs to be confirmed that CYP 
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mRNA of ENDO (E7) and (E11) were taken as representative samples to express CYP1B1 and 
CYP1A1 for titration study. 
 
Serial dilution was done as follows and PCR amplification was done with similar conditions for 
30 cycles and quantification was estimated with densitometric analysis. 
Lane 1: 2ml of cDNA of E11. 
Lane 2: 2ml of (2ml of cDNA + 2 ml DEPC water) 
Lane 3: 2ml of (2ml of item #2 + 2ml DEPC water) 
Lane 4: 2ml of (2ml of item # 3 + 2ml DEPC water) 
Lanes 5 to 8 as above with E7  
Lane 9: +ve control 
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Materials and Equipment  
Chloroform (ACS grade) 
Isopropanol (ACS grade) 
Ethanol (ACS grade) 
RNA stat-60 (100ml or 200 ml bottle containing a red solution of RNA stat-60 which contains 
phenol and guanidinium thiocyanate in a monophase solution) obtained from TEL-TEST B, 
inc., PO BOX 1421, 1511 County road 129, Friendswood, TX 77546. 1-800-631-0600.) 
Liquid nitrogen 
Primers designed using oligo and dnasis software and obtained from Gibco-BRL, Gaithersburg, 
MD, USA. 
Reverse Transcription reaction Buffer  Gibco-BRL 
M-MLV Reverse Transcriptase  - Gibco-BRL 
10mM Dithiothreitol (DTT)- Gibco-BRL 
Oligo (dT)- Gibco-BRL 
DNTP- Gibco-BRL 
25mM Magnesium chloride- Gibco-BRL 
Taq polymerase - Promega Corporation 
Primers for -Actin - Clonetech, Palo Alto, CA, USA 
Control RNA (891-bp CAT derived)- Clonetech, Palo Alto, CA, USA 
DNA size markers  Bio-Rad,  
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Agarose  - FMC 
BiS- Acrylamide (N,N-methylene bisacrylamide )- Sigma 
Ammonium per sulphate - Sigma 
Temed - sigma 
Tris Hydrochloride - Sigma 
Qia quick purification kits - Qiagen 
Qia quick gel extraction kits - Qiagen 
10X SSC 
α- 32P dCTP  radionucleotides ( Redivue Nucleotides) -  Amersham pharmacia 
0.1% Sodium Dodecyl Sulphate (SDS) -Sigma 
Formamide - Sigma 
Sodium phosphate (monobasic and dibasic salts)  Fisher Scientific 
Sodium Chloride  Fisher Scientific 
EthylenediaminetetraaceticAcid (EDTA) solutions - Sigma 
Salmon Sperm DNA  Promega Corporation 
Random prime kit- Gibco-BRL 
5- End labelling kit  Promega Corporation 
Sodium Hydroxide solutions  Fisher Scientific 
TBE buffer 
Buffered phenol chloroform  Gibco-BRL 
Ethidium bromide solution - Sigma 
Di Ethyl Pyro carbonate (DEPC) - Sigma 
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Formaldehyde  Fisher Scientific 
Sodium Acetate  Fisher Scientific 
MOPS  Sigma 
Eppendorf tubes (centrifuge tubes) 
Mortar and pessle 
Perkin  Elmer Thermal cycler system 2400 and 480  PE Biosystems. 
Thin walled PCR Tubes- Fisher Scientific, Pittsburgh.  PA, USA 
Eagles eye software and hardware. 
Optimas software, 
Phosphor Imager,  
Photo plates for Phosphor imager 
Imagequant software 
Zeta probe Nylon membranes  - Bio-rad 
G-50 sephadex columns - Boehringer Mannheim 
UV Cross linker - Stratagene 
Electrophoresis apparatus - Owl apparatus 
Hybridization oven   Stovall. 
Spectrphotometer  Beckman 
Polypropylene tubes 13ml 17X75 mm  Molecular Research center, Inc. 
-700C Freezer 
Ultra centrifuge- Beckmann 




1. Loading Buffer for RNA: 
  Formamide  750l 
20X Mops  75l 
Glycerol  100l 
Formaldehyde  240l 
0.5% DEPC water  540l 
Bromophenol blue  a pinch (about 2.5%) 
2. Formaldehyde Gel (for 14 well large cast) 
Agarose  50ml 
Formaldehyde- 2.7ml 
Ethydium bromide  2.0 l 
3.Running Buffer for Formaldehyde Gel 
20X mops 30ml 
Ethydium Bromide 20 l 
Formaldehyde  20ml 
0.5% DEPC water QS  600 ml 
4. 10X SSC 
3M Sodium chloride  175 gm 
0.3M Sodium Citrate  88.2gm 
Water q.s  ----- 200 ml 
Adjust PH to 7.0 with 1M HCl and make volume to 1 Litre. 
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5. MOPS  20X 
0.4M MOPS  PH 7.0 
0.16M Sodium Acetate 
0.02M EDTA  PH 8.0 
Adjust PH to 7.0 with 2N NaoH 
sterile filter with 0.2mm millipore filter 
6. 0.5% DEPC water 
Add 5gm of DEPC in 5 litre of milliq water.  Keep overnight, filter and autoclave and 
store at 40C. 
7. TBE buffer  1 litre contains 
100mM Tris 
90mM Boric acid 
1.0mM EDTA 













Patientss Name:     Hospital  ID#: 
 
       Pathology ID#: 
 






Address:      Telephone Number: 
 
 






Number of cigarettes Smoked:    Number of Years smoking cigarettes 
 
 

















RNA concentrations from the tissues and their 
identifications of all patients. 
     
Tissues used for 1A1 and 1B1 expression  
     
PT # Endometrium Squamous Cervix Name 
1 4.288 0.967 0.345 BM 
2 3.767 0.193 na BJ 
3 4.443 1.028 0.633 WD 
4 0.267 0.136 0.218 DS 
5 1.004 1.208 0.512 VL 
6 6.329 1.042 4.409 GJ 
7 8.209 1.15 3.11 BG 
8 9.57 1.65 3.53 WB 
9 10.498 1.032 2.42 LS 
10 7.126 2.79 2.13 PC 
11 6.413 1.64 2.06 ED 
12 2.628 2.13 2.25 VS 
13 3.94 1.63 1.53 RN 
14 2.01 0.308 1.45 BC 
15 8.1 1.498 2.28 VD 
16 1.51 1.62 3.09 CH 
17 3.305 1.16 NA BC 
18 1.27 0.732 3.779 BL 
19 0.458 1.038 0.364 VM 
20 1.74 2.68 1.388 HD 
21 0.107 2.407 1.966 WD 
22 0.813 NA 0.344 BW 
     
Tissues used for CYP 3A expression  




Conc Cerv ID # Conc Name 
E31 3.247 C51 1.11 KS 
E32 3.982 C52  0.96 DD 
E33 4.995 C53 1.43 HR 
E34 6.161 C54 1.68 BG 
E35 3.46 C56 1.17 LH 
E36 2.878 C57 0.58 KC 
E37 2.74 C58 0.49 BC 
E38 3.913 C59 1.56 LF 
E39 3.9 C60 5.16 YH 
E40 3.175 C61 1.3 TD 
E41 7.241 C62 4.92 MP 
E42 3.159 C63 1.63 PK 







Master Data – Expression levels of CYP3A3/A4 and CYP3A7 as ratio to β-
Actin and the relative differences 
 
ID# stage SM/NS En3A3/4 Cer3A3/4 Endo3A7 cerv3A7 (E-C)3A3/4(E-C)3A7 E(3A3/4-3AC(3A3-3A7
BW p SM 0 . 0 . 0
RA p NS 0 . 0 . 0
HS p SM 950517 . 14223601 . -1.3E+07
GJ p NS 2152962 . 91058 . 2061904
VD p NS 0 . 0 . 0
DS p NS 3128568 . 10664064 . -7535496
DN p SM 4619279 . 9430575 . -4811296
BL p NS 8971099 . 2659004 . 6312095
BM p NS 0 . 127022 . -127022
BG p SM 6976845 . 19244217 . -1.2E+07
WB p SM 0 . 0 . 0
PC p SM 7769961 12748 5457450 59205 7757213 5398245 2312511 -46457
WD s NS 4243992 18427 95210 533427 4225565 -438217 4148782 -515000
BJ s NS 2403039 . 10567 . 2392472
BC s SM 26821 . 390583 . -363762
LS s SM 432695 0 154682 0 432695 154682 278013 0
ED s SM 42844 30978 34066 615701 11866 -581635 8778 -584723
RA s NS 6938609 0 81577 922991 6938609 -841414 6857032 -922991
BC s NS 8473469 0 114550 0 8473469 114550 8358919 0
VD s NS 4252467 0 1146260 1111309 4252467 34951 3106207 -1111309
CH s NS 5853757 0 1053534 0 5853757 1053534 4800223 0
KS a NS 16144.86 8260.72 593082 619157.8 7884.14 -26075.8 -576937 -610897
DD s SM 5188.64 -44.35 59660.02 35017.32 5232.99 24642.7 -54471.4 -35061.7
HR p NS 56258.25 1754.84 1014889 18999.14 54503.41 995890.1 -958631 -17244.3
BG p NS 22997.22 -4.95 1032549 9095.2 23002.17 1023453 -1009551 -9100.15
LH s NS 5060.3 1411.7 61469.89 10089.04 3648.6 51380.85 -56409.6 -8677.34
KC s SM 109528.2 3002.82 899699.7 19757.01 106525.4 879942.7 -790171 -16754.2
BC s NS 374089.3 -125.59 295883.6 -205.07 374214.9 296088.7 78205.68 79.48
LF p NS 33689.78 -467.82 256547.4 536.31 34157.6 256011.1 -222858 -1004.13
YH a NS 53867.4 2636.4 1521953 14631.52 51231 1507322 -1468086 -11995.1
TD p NS 96553.12 1422.36 428051.7 8284.52 95130.76 419767.2 -331499 -6862.16
MP s NS 274711.9 29144.06 574076.6 9226.17 245567.8 564850.4 -299365 19917.89
PK p NS 68775.67 2312.09 29237.53 14586.55 66463.58 14650.98 39538.14 -12274.5





The expression of CYP3A3/A4 - Model with no interaction:  
 
Response:  3A3/A4 
Summary of Fit 
RSquare 0.168844 
RSquare Adj 0.138061 
Root Mean Square Error 2287082 
Mean of Response 1206368 
Observations (or Sum Wgts) 57 
 
Effect Test 
Source Nparm DF Sum of Squares F Ratio Prob>F 
SM/NS 1 1 1.78821e12 0.3419 0.5612 
REGION 1 1 5.54076e13 10.5927 0.0020 
 
Whole-Model Test 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 2 5.73801e13 2.869e13 5.4849 
Error 54 2.8246e+14 5.231e12 Prob>F 




 Sum of Squares F Ratio DF Prob>F 
 1.78821e12 0.3419 1 0.5612 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
NS 1152879.963  391487.9228 1353852 




 Sum of Squares F Ratio DF Prob>F 
 5.54076e13 10.5927 1 0.0020 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
C -33905.345  481662.5047 5643 








The expression of CYP3A3/A4 - Model with interaction: 
 
Response:  3A3/A4 
Summary of Fit 
RSquare 0.172498 
RSquare Adj 0.125659 
Root Mean Square Error 2303477 
Mean of Response 1206368 
Observations (or Sum Wgts) 57 
 
Effect Test 
Source Nparm DF Sum of Squares F Ratio Prob>F 
SM/NS 1 1 1.21595e12 0.2292 0.6341 
REGION 1 1 4.90422e13 9.2428 0.0037 
SM/NS*REGION 1 1 1.24185e12 0.2340 0.6305 
 
Whole-Model Test 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 3 5.86219e13 1.954e13 3.6827 
Error 53 2.81218e14 5.306e12 Prob>F 




 Sum of Squares F Ratio DF Prob>F 
 1.21595e12 0.2292 1 0.6341 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
NS 1128939.734  397387.4840 1353852 




 Sum of Squares F Ratio DF Prob>F 
 4.90422e13 9.2428 1 0.0037 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
C 5995.036  492076.3279 5643 































 Sum of Squares F Ratio DF Prob>F 
 1.24185e12 0.2340 1 0.6305 
 
Least Squares Means 
Level Least Sq Mean  Std Error 
NS,C 4376.772  615630.0431 
NS,E 2253502.695  502659.8253 
SM,C 7613.300  767825.5661 





The expression of CYP3A7- Model with out interaction: 
 
 
Response:  3A7  
Summary of Fit 
RSquare 0.116652 
RSquare Adj 0.083935 
Root Mean Square Error 3435458 
Mean of Response 1357512 
Observations (or Sum Wgts) 57 
 
Effect Test 
Source Nparm DF Sum of Squares F Ratio Prob>F 
SM/NS 1 1 3.60521e13 3.0546 0.0862 
REGION 1 1 4.88614e13 4.1400 0.0468 
 
Whole-Model Test 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 2 8.41631e13 4.208e13 3.5655 
Error 54 6.37328e14 1.18e+13 Prob>F 




 Sum of Squares F Ratio DF Prob>F 
 3.60521e13 3.0546 1 0.0862 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
NS 544851.761  588059.6219 733579 




 Sum of Squares F Ratio DF Prob>F 
 4.88614e13 4.1400 1 0.0468 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
C 418070.379  723512.1544 240493 





The expression of CYP3A7- Model with interaction: 
 
 
Response:  3A7  
Summary of Fit 
RSquare 0.157827 
RSquare Adj 0.110157 
Root Mean Square Error 3385933 
Mean of Response 1357512 
Observations (or Sum Wgts) 57 
 
Effect Test 
Source Nparm DF Sum of Squares F Ratio Prob>F 
SM/NS 1 1 2.36864e13 2.0661 0.1565 
REGION 1 1 6.45753e13 5.6326 0.0213 
SM/NS*REGION 1 1 2.97075e13 2.5913 0.1134 
 
Whole-Model Test 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 3 1.13871e14 3.796e13 3.3108 
Error 53 6.07621e14 1.146e13 Prob>F 




 Sum of Squares F Ratio DF Prob>F 
 2.36864e13 2.0661 1 0.1565 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
NS 661943.652  584128.8916 733579 




 Sum of Squares F Ratio DF Prob>F 
 6.45753e13 5.6326 1 0.0213 
 
Least Squares Means 
Level Least Sq Mean  Std Error Mean 
C 222917.228  723314.1745 240493 































 Sum of Squares F Ratio DF Prob>F 
 2.97075e13 2.5913 1 0.1134 
 
Least Squares Means 
Level Least Sq Mean  Std Error 
NS,C 303766.621  904928.588 
NS,E 1020120.682  738871.098 
SM,C 142067.836  1128644.245 












3A3/A4 (Endo - Cerv) 
Quantiles 
maximum 100.0% 8473469 
  99.5% 8473469 
  97.5% 8473469 
  90.0% 7552553 
quartile 75.0% 4252467 
median 50.0% 95130.8 
quartile 25.0% 34157.6 
  10.0% 6189.92 
  2.5% 3648.6 
  0.5% 3648.6 




Std Dev 3018268 
Std Error Mean 779313 
Upper 95% Mean 3718102 
Lower 95% Mean 375188 
N 15 
Sum Weights 15 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate 2046645 
 
  t Test 
Test Statistic 2.6262 
Prob > |t| 0.0199 
Prob > t 0.0100 
Prob < t 0.9900 
 
3A7 (Endo - Cerv) 
Quantiles 
maximum 100.0% 1507322 
  99.5% 1507322 
  97.5% 1507322 
  90.0% 1235049 
quartile 75.0% 995890 
median 50.0% 256011 
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quartile 25.0% 14651 
  10.0% -599496 
  2.5% -841414 
  0.5% -841414 




Std Dev 615457.1 
Std Error Mean 158910.3 
Upper 95% Mean 675944.2 
Lower 95% Mean -5711.8 
N 15.0 
Sum Weights 15.0 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate 335116 
 
  t Test 
Test Statistic 2.1088 
Prob > |t| 0.0535 
Prob > t 0.0267 















maximum 100.0% 7757213 
  99.5% 7757213 
  97.5% 7757213 
  90.0% 7757213 
quartile 75.0% 2263824 
median 50.0% 192003 
quartile 25.0% 10207.7 
  10.0% 5232.99 
  2.5% 5232.99 
  0.5% 5232.99 




Std Dev 3103198 
Std Error Mean 1266875 
Upper 95% Mean 4688394 
Lower 95% Mean -1824724 
N 6 
Sum Weights 6 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate 1431835 
 
  t Test 
Test Statistic 1.1302 
Prob > |t| 0.3097 
Prob > t 0.1548 
Prob < t 0.8452 
 
3A7 (Endo - Cervix) 
Quantiles 
maximum 100.0% 5398245 
  99.5% 5398245 
  97.5% 5398245 
  90.0% 5398245 
quartile 75.0% 2009518 
median 50.0% 124588 
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quartile 25.0% -126927 
  10.0% -581635 
  2.5% -581635 
  0.5% -581635 




Std Dev 2206636 
Std Error Mean 900856 
Upper 95% Mean 3310751 
Lower 95% Mean -1320627 
N 6 
Sum Weights 6 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate 995062 
 
  t Test 
Test Statistic 1.1046 
Prob > |t| 0.3196 
Prob > t 0.1598 














maximum 100.0% 8358919 
  99.5% 8358919 
  97.5% 8358919 
  90.0% 6693551 
quartile 75.0% 3366851 
median 50.0% 0 
quartile 25.0% -392858 
  10.0% -1.33e6 
  2.5% -7.54e6 
  0.5% -7.54e6 




Std Dev 3439126 
Std Error Mean 733224 
Upper 95% Mean 2687062 
Lower 95% Mean -362560 
N 22 
Sum Weights 22 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate 1162251 
 
  t Test 
Test Statistic 1.5851 
Prob > |t| 0.1279 
Prob > t 0.0639 




maximum 100.0% 19917.9 
  99.5% 19917.9 
  97.5% 19917.9 
  90.0% 8014.84 
quartile 75.0% 0 
median 50.0% -9100.2 
quartile 25.0% -515000 
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  10.0% -998318 
  2.5% -1.11e6 
  0.5% -1.11e6 




Std Dev 381793.3 
Std Error Mean 98578.6 
Upper 95% Mean -2394.2 
Lower 95% Mean -425253.4 
N 15.0 
Sum Weights 15.0 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate -213824 
 
  t Test 
Test Statistic -2.1691 
Prob > |t| 0.0478 
Prob > t 0.9761 













maximum 100.0% 2312511 
  99.5% 2312511 
  97.5% 2312511 
  90.0% 1702162 
quartile 75.0% 135476 
median 50.0% -2.72e4 
quartile 25.0% -3.81e6 
  10.0% -1.3e+7 
  2.5% -1.33e7 
  0.5% -1.33e7 




Std Dev 5107828 
Std Error Mean 1474503 
Upper 95% Mean 846776 
Lower 95% Mean -5643967 
N 12 
Sum Weights 12 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate -2.4e+6 
 
  t Test 
Test Statistic -1.6267 
Prob > |t| 0.1321 
Prob > t 0.9340 
Prob < t 0.0660 
 
Cervix  (3A3-3A7) 
Quantiles 
maximum 100.0% 0 
  99.5% 0 
  97.5% 0 
  90.0% 0 
quartile 75.0% -3958 
median 50.0% -25908 
quartile 25.0% -181024 
  10.0% -584723 
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  2.5% -584723 
  0.5% -584723 




Std Dev 230930.2 
Std Error Mean 94276.9 
Upper 95% Mean 127630.7 
Lower 95% Mean -357055.1 
N 6.0 
Sum Weights 6.0 
 
Test Mean=value 
Hypothesized Value 0 
Actual Estimate -114712 
 
  t Test 
Test Statistic -1.2168 
Prob > |t| 0.2780 
Prob > t 0.8610 
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